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ABSTRACT 
Osteochondrosis and traumatic osteochondral defects are debilitating disorders 
affecting articular cartilage of millions of human and veterinary species. As articular 
cartilage is highly specialized and lacks reparative capacity, focal osteochondral defects 
(FODs) lead to a chronic progressive disease state and subsequent widespread 
osteoarthritis.  While medical and surgical management options are available, they are 
not without complications. To address these limitations, recent work in the field of 
regenerative medicine has focused on the use of mesenchymal stem cells (MSCs) and 
three-dimensional (3D) scaffolds to develop tissue engineering constructs to replace 
injured articular cartilage restoring function and eliminating clinical signs. While much 
work has been performed in human MSC tissue engineering, canine MSC (cMSC) tissue 
engineering for the treatment of osteochondral defects remains in its infancy. The 
objective of the work presented herein was to develop an improved 3D serum free 
system for cMSC chondrogenesis and determine the effect of dose and combination of 
three important chondrogenic growth factors (TGF-3, BMP-2 and bFGF) using bone 
marrow-derived cMSCs. 
During phase 1, the effect of ten growth factor combinations on cMSC 
chondrogenesis was determined using construct morphometry, live/dead staining, and 
histology. High doses of BMP-2 and bFGF produced heavier, larger, consistently shaped 
constructs when compared to lower doses. Based on these results, in phase 2, the effect 
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of dexamethasone, TGF-3, and high concentrations of BMP-2, and bFGF were 
assessed using quantitative assays of cytotoxicity, glycosaminoglycan (GAG) 
accumulation, and gene transcription. In the presence of bFGF, evidence of reduced cell 
stress suggested a potential role in cell survival during initial stages of chondrogenesis 
when the cells initiate a condensation event. Moreover, the presence of BMP-2 and 
bFGF in chondrogenic media resulted in the highest accumulation of GAG.  Gene 
expression studies demonstrated that upregulation of genes associated with 
chondrogenesis and osteogenesis occurred in a time-dependent manner. Ultimately, this 
work demonstrates that the 3D serum-free collagen type I system described is useful for 
assessing canine chondrogenic differentiation. Collectively, this work describes the 
effect of chondrogenic growth factors on cMSCs in combination with a 3D collagen type 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
ARTICULAR (HYALINE) CARTILAGE 
Articular cartilage, also referred to as hyaline cartilage, is a specialized 
connective tissue located in diarthrodial joints. The function of articular cartilage is to 
facilitate locomotion by providing a lubricated surface with a very low coefficient of 
friction for joint articulation and load transmission (Sophia Fox et al., 2009). To 
accomplish this task, both the cellular arrangement and extracellular matrix (ECM) 
composition and arrangement are highly specialized. A detailed discussion of the 
cellular and ECM arrangements will be provided below. Importantly, while the cellular 
and ECM arrangements are unique, the reader should note that normal articular cartilage 
lacks blood vessels, lymphatics and nerves (Sophia Fox et al., 2009). Recent studies 
have demonstrated that the in vivo cartilage thickness in the stifle joint (knee joint in 
human beings) is 0.6-1.3 mm in dogs and 2.2-2.5 mm in human beings (Frisbie et al., 
2006).  
The ECM is a major structural component of articular cartilage. The ECM of 
articular cartilage consists of components including collagen, proteoglycans other non-
collagenous proteins, glycoproteins, and water (Sophia Fox et al., 2009). Water 
contributes up to approximately 80% of the weight of healthy articular collagen, with 
approximately 30% of water content tightly associated with the intrafibrillar space of 
collagen. The remaining water is located within physical pore spaces located within the 
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ECM. (Maroudas et al., 1991; Torzilli, 1985). In healthy articular cartilage, water 
content decreases as the depth of cartilage increases (Buckwalter and Mankin, 1997), 
and it is this flow of water that is involved in the transport and distribution of nutrients to 
chondrocytes (Sophia Fox et al., 2009).  
A critical component of articular cartilage ECM is the fibrillary network of 
structurally supporting collagen, of which collagen type II accounts for approximately 
80% of the articular cartilage ECM (Gelse et al., 2003). Similar to all helical collagens, 
collagen type II is composed of a triple helix of three collagen monomer chains. Each 
collagen type varies in tissue-specific expression and synthesis of structural proteins and 
glycoprotein components, which result in the unique functional and biologic 
characteristics of the specific cartilage at distinct locations (Gelse et al., 2003). Collagen 
type II is composed of three identical -chains (referred to as a homotrimer) and is 
found not only in articular cartilage but in the vitreous body and nucleus pulposus (Gelse 
et al., 2003).  
Compared to collagen type I, the most abundant collagen in the body, collagen 
type II chains interact with proteoglycans and thus have higher contents of 
hydroxylysine, glucosyl and galactosyl residues (Mayne, 1989). In addition, the self-
assembly of collagen type II has been suggested to be more complex than that of 
collagen type I (Fertala et al., 1994).  In addition to collagen type II, articular cartilage 
also contains lower amounts of collagen type III, VI, IX, X, XI, XII and XIV that 
contribute to the mature matrix (Eyre, 2002). 
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In addition to the collagens detailed above, proteoglycans account for 10-15% 
of the wet weight of the ECM and are the second largest group of ECM 
macromolecules present in articular cartilage (Sophia Fox et al., 2009). Proteoglycans 
are composed of a protein core with a varying number of linear glycosaminoglycan 
chains covalently attached which can be composed of more than 100 monosaccharides 
(Sophia Fox et al., 2009). Important proteoglycans of healthy articular cartilage include: 
aggrecan, decorin, biglycan, and fibromodulin (Sophia Fox et al., 2009). Aggrecan is a 
highly negatively charged molecule that maintains water content and provides osmotic 
properties, allowing cartilage to resist repetitive compressive loads.  Additionally, 
aggrecan binds to the large glycosaminoglycan hyaluronan (HA) to form large 
proteoglycan aggregates (Sophia Fox et al., 2009). Decorin and fibromodulin contribute 
to interfibril interactions and normal collagen fibrillogenesis through their interactions 
with collagen type II (Sophia Fox et al., 2009). 
A final group of articular cartilage ECM proteins include the non-collagenous 
proteins which constitute a smaller proportion of articular cartilage. Some examples of 
these include fibronectin, anchorin CII, oligomeric protein, fibronectin and tenascin. 
Their role has not been fully characterized however, it has been suggested that they play 
a role in organization and maintenance of the ECM (Sophia Fox et al., 2009).  
Chondrocytes are the specialized cartilage cells responsible for both synthesis 
and digestion of the extracellular matrix through the secretion of cytokines, which is 
crucial for cartilage homeostasis (Pearle et al., 2005). Importantly, although a critical 
component of articular cartilage, chondrocytes account for only approximately 5% of 
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the wet weight of articular cartilage. Chondrocyte injury, apoptosis, or necrosis 
commonly results in a progressive loss of normal cartilage ECM due to a poor inherent 
reparative capacity of this unique tissue.  
 
CARTILAGE INJURY 
Developmental and traumatic joint diseases, such as osteochondrosis (OC), 
osteochondritis dissecans (OCD) and traumatic focal osteochondral defects (FODs), are 
debilitating articular cartilage lesions affecting millions of humans and veterinary 
species. These conditions specifically affect articular cartilage and, due to the inherently 
poor reparative capacity of articular cartilage, result in a chronic progressive disease 
state and subsequent widespread osteoarthritis (OA) of the affected joint.  OC/OCD and 
FODs thus lead to a reduced quality of life for patients while representing a tremendous 
economic and clinical burden to both the veterinary and human health-care industries. 
The economic impact of osteoarthritis in humans approaches 60 billion dollars per year 
(Buckwalter et al., 2004) affecting more than 20 million people in the United States 
(Pearle et al., 2005). Although the actual economic impact on veterinary species is 
unknown, it was recently shown that pet owners spend 1.32 billion dollars annually on 
the treatment from cranial cruciate ligament ruptures, of which OA is an important 
component of the disease process (Wilke et al., 2005).  
OC/OCD was originally described in veterinary medicine in the 1960s (Ytrehus 
et al., 2007). OC is defined as a multifocal disease of epiphyseal cartilage with many risk 
factors including: rapid growth, heredity, anatomic characteristics, trauma and dietary 
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factors (Ytrehus et al., 2007). With regards to repair, articular cartilage defects that do 
not penetrate the subchondral bone are unable to spontaneously repair (Fuller and 
Ghadially, 1972). Even with full thickness defects, multiple predisposing factors such as 
age, defect size and location may dictate whether or not repair occurs. Furthermore, 
repair of small defects usually occurs through the production of hyaline cartilage, 
however, larger defects repair with fibrous tissue (Coventry et al., 1972). This change in 
tissue type is biomechanically and biochemically different from hyaline cartilage and 
thus, further degeneration occurs (Shelbourne et al., 2003) leading to progression of OA.   
Unfortunately, the etiology of osteochondrosis is not fully understood due to a 
lack of knowledge of the pathogenesis of the primary lesion.  However, we do recognize 
that OC/OCD results from altered or abnormal endochondral ossification. Several main 
hypotheses have been formulated with regards to the pathogenesis of the abnormal 
endochondral ossification: the first is centered upon apoptosis of the endothelium lining 
cartilage canal vessels, the second is centered upon microtrauma to the vessels of the 
metaphysis, and the third is centered on altered cellular signaling between the molecules 
parathyroid hormone related peptide (PTHRP), indian hedgehog (Ihh), and TGF-3 
(Ytrehus et al., 2007). With regards to the first hypothesis, during skeletal development 
the blood supply to the physeal plate (i.e. the growth plate) closest to the metaphysis is 
somewhat limited. If this limited blood supply is focally interrupted, an area of focal 
ischemic necrosis results. As the bone continues to elongate, this focal area of cartilage 
will resist blood vessel invasion thus preventing the normal ossification process of the 
cartilage above the defect (Ytrehus et al., 2007). The second hypothesis centers around 
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microtrauma to the vessels of the metaphysis and could, in a similar manner to the first 
hypothesis, cause interruption of blood supply and a failure of differentiation of the 
hypertrophic cartilage leading to a persistent thickened physeal cartilage (Ytrehus et al., 
2007). This thickened necrotic cartilage can fissure resulting in a flap of cartilage 
exposing the underlying bone and leading to the pain and lameness observed clinically. 
This separation of the flap of cartilage from the underlying bone is then termed an OCD 
lesion (Ytrehus et al., 2007).  
Articular cartilage can also be traumatically injured. Initially, traumatic injury to 
articular cartilage often leads to small, focal osteochondral defects (FODs). These FODs 
can be caused by high impact athletic activities that lead to localized blunt trauma to a 
specific region of the articular cartilage.  While some of these injuries induce temporary 
cartilage injury and subchondral bone bruising, other athletic injuries lead to thinning of 
articular cartilage, apoptosis of chrondrocytes and progressive OA.  
OA is a multifactorial disease with an incompletely characterized 
etiopathogenesis. The disease is generally characterized by aberrant repair and eventual 
degradation of articular cartilage in association with alterations in subchondral bone 
metabolism, periarticular osteophytosis and a variable degree of synovial inflammation  
(Innes, 2012). Macroscopic changes in osteoarthritis can include softening 
(chondromalacia), fibrillation, and erosions (ulceration) (Noyes and Stabler, 1989). 
Idiopathic or primary osteoarthritis refers to that caused by aging (most common in 
humans but rare in veterinary species) and secondary osteoarthritis occurs to that caused 
by a preceding event (Innes, 2012). The two types do not differ from a pathologic basis 
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with the exception of primary cause. Proteolytic enzymes known as matrix 
metalloproteases (MMPs) are responsible for cartilage matrix degradation, mainly 
MMP-13 and MMP-1 (interstitial collagenases), MMP-3 (stromelysins), and MMP-2 
and MMP-9 (gelatinases) (Martel-Pelletier, 2004; Reboul et al., 1996). Usually MMPs 
are kept controlled in a homeostatic state by tissue inhibitors of MMPs (TIMPs) 
however, in osteoarthritis an imbalance occurs leading to the destruction of collagen type 
II (Martel-Pelletier, 2004) and proteoglycans such as aggrecan. The precise cause of this 
imbalance is not completely understood however, there is evidence that acute 
mechanical overload, cyclic/fatigue loading, and cytokines (such as TNF-, IL-1 and 
IL-6) lead to the disruption of cartilage homeostasis (Lin et al., 2004; Martel-Pelletier, 
2004).  
As detailed above, both human beings and veterinary species are affected by 
OC/OCD and athletically induced joint injuries, both of which result in FODs. In both 
species, the end result is progressive OA. The dog is an excellent translational model for 
many human diseases (Hoffman and Dow, 2016). OA is included as one of these disease 
models along with intervertebral disc degeneration, dilated cardiomyopathy, 
inflammatory bowel diseases, Crohn’s fistulas, meningoencephalomyelitis (multiple 
sclerosis-like), keratoconjunctivitis sicca (Sjogren’s syndrome-like), atopic dermatitis 
and chronic (end stage) kidney disease (Hoffman and Dow, 2016). Using companion 
animals, such as dogs, in clinical studies allows scientists to evaluate feasibility, safety 
and efficacy of novel treatment strategies, for example cell-based therapies, for 
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subsequent translation into human beings (Hoffman and Dow, 2016). At present, 
treatment options for OA are very similar between canines and human beings.  
 
TREATMENT OF OSTEOARTHRITIS 
Broadly, there are two primary categories of OA treatment: medical and surgical 
management. Medical management of OA typically involves a multimodal approach. 
This approach includes a combination of the following: activity control, weight 
management, nutritional support, physical therapy, and administration of a nonsteroidal 
anti-inflammatory drug, analgesic medications, nutraceuticals and purported slow-acting 
drugs of osteoarthritis (Aragon et al., 2007). While medical management is often used to 
treat patients with early FODs, medical management is often life long and requires the 
addition of new treatments or drugs as time progresses. In addition to life-long treatment, 
the strongest evidence for the alleviation of clinical signs is limited to non-steroidal anti-
inflammatory medications (Aragon et al., 2007). These medications are not without 
adverse effects some of which include gastrointestinal disturbances, liver injury, and/or 
kidney failure (Doig et al., 2000; Forsyth et al., 1998; Moreau et al., 2003; Nell et al., 
2002). 
When medical management does not alleviate symptoms, surgical treatment is 
often pursued. A fundamental principle of treating focal cartilage defects is that early 
intervention is essential to the success of the procedure. There are a myriad of surgical 
treatment options for articular cartilage defects which can be divided into two broad 
categories: palliative versus restorative treatments. Palliative treatments focus on both 
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removing sources of irritation and inflammation (arthroscopic removal of fragments) 
(Cole et al., 2009) as well as enhancing the formation of a fibrocartilage membrane over 
the defect (which, importantly, does not restore structure or function). This is 
accomplished through procedures such as debridement, abrasion arthroplasty, and 
microfracture. With regards to debridement and fragment removal, clinical outcome may 
be poor for up to 25% of cases (Rudd et al., 1990). Microfracture is particularly 
advantageous due to the minimally invasive nature of the procedure, the short 
postoperative recovery time and the cost effectiveness (Clair et al., 2009). However, 
success is based upon early surgical intervention and the young age of the patient (Clair 
et al., 2009). Unfortunately, in veterinary patients, such as dogs, early diagnosis and 
intervention are often not possible due to the stoic nature of veterinary patients and the 
inability of most veterinary clients to recognize early clinical signs associated with 
OC/OCD or FODs and early OA. These important considerations often result in poor 
long-term function when microfracture is used to treat veterinary patients. Furthermore, 
depressed and thinned repair cartilage, incomplete peripheral integration and 
subchondral bony overgrowth have been observed in 25-40% of cases (Brown et al., 
2004; Mithoefer et al., 2005).  
In contrast, restorative treatments attempt to repair or replace the cartilage defect 
and fully restore structure and function through procedures such as autologous 
osteochondral transplants (i.e. OATS), autologous chondrocyte implantation (ACI), or 
placement of allogenic osteochondral tissue grafts or synthetic cartilage substitutes.  
Osteochondral autograft transplantation involves harvesting osteochondral grafts (both 
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articular cartilage and underlying subchondral bone) from areas of limited weight-
bearing and placing them into FODs (Fitzpatrick et al., 2010). OATS procedures have 
been used in knee FODs of human beings with a superior outcome compared to 
microfracture (Gudas et al., 2005). In one study by Fitzpatrick et al, osteochondral grafts 
were obtained from joints other than the affected joint. For example, using a stifle 
osteochondral graft to treat an osteochondral lesion in the shoulder (Fitzpatrick et al., 
2010). Whether or not this causes further lameness has not yet been determined. The 
benefit however of autologous chondrocyte implantation is the ability to expand 
chondrocytes to fill defects up to at least 10cm2 (Knutsen et al., 2004). In one 
randomized control trial in humans, a significant difference was not noted between 
autologous chondrocyte implantation compared with microfracture with the exception of 
significantly more improvement in multipurpose health survey (SF -36) in the first two 
years in the microfracture group versus the autologous chondrocyte implantation group 
(Knutsen et al., 2004). There was no difference between the treatment groups in terms of 
macroscopic or histological results however, the number of biopsy specimens examined 
was low (Knutsen et al., 2004). Some limitations noted with autologous chondrocyte 
implantation include: limited availability of autologous chondrocytes, de-differentiation 
of these cells during culture, graft failure and the cost and morbidity associated with two 
separate surgical procedures (one for harvest and a second for implantation) (Brittberg et 
al., 1994; Knutsen et al., 2004; Matsumoto et al., 2010; Redman et al., 2005). In 
conclusion, while a number of medical and surgical treatments exist for the management 




Although restorative treatments are performed in both human and veterinary 
medicine, they are not without complication, such as: donor site morbidity (Feczkó et al., 
2003; Reddy et al., 2007; Szerb et al., 2005b), cartilage thickness discrepancies (Breur 
and Lambrechts, 2012), poor graft survival, and progression of OA (Breur and 
Lambrechts, 2012). To navigate these obstacles, much recent work has focused on 
regenerative medicine as a potential restorative treatment for FODs. 
 Regenerative medicine is defined as an interdisciplinary field of research and 
clinical application focused on the repair, replacement or regeneration of cells, tissues or 
organs to restore impaired function resulting from any cause, including congenital 
defects, disease, trauma and aging (Daar and Greenwood, 2007). One method by which 
regenerative medicine may be used to treat patients with focal articular cartilage defects 
is the direct injection of mesenchymal stem cells (MSCs) into the affected joint 
(Emadedin et al., 2012). Mesenchymal stem cells, also known as multipotent stromal 
cells or marrow stromal cells, are progenitor cells of mesenchymal origin which are 
capable of differentiating within the mesenchymal line into a variety of specialized 
tissues including bone, fat, and cartilage (Caplan and Correa, 2011; Dominici et al., 
2006). MSCs have been defined by Dominici et al. as spindle-shaped cells that are 
adherent to plastic, have specific cell surface antigen expression and have multipotent 
differentiation potential (Dominici et al., 2006). The cells must be positive for CD105, 
CD73 as well as CD90 and be negative for CD45, CD34, CD14 or CD11b, CD79 or 
CD19 and HLA-DR (Dominici et al., 2006). Although injecting MSCs in solution into 
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the joint is relatively straightforward and the most common method by which human and 
veterinary patients currently receive stem cell therapy, studies have shown that few cells 
remain at the injection site 50 days after multiple deliveries at different time points 
(Krause et al., 2010). Additionally, engraftment and differentiation into specialized cells 
needed for restoration of cartilage is limited due to lack of a matrix or signaling allowing 
the majority of cells to die or migrate away from the site of interest (Krause et al., 2010). 
In contrast to this finding, Horie et al. illustrated that synovium and bone marrow 
derived mesenchymal stem cells adhered and promoted regeneration of a meniscal lesion 
without the cells mobilizing to organ sites (Horie et al., 2009). These Lacz+ tagged 
MSCs produced measurable photon readings could be detected up to 28 days. However, 
similar to the findings by Krause et al., no photons could be detected at a longer time 
point (Horie et al., 2009) and thus cells did not remain at the site of injury. Whether 
positive short- or medium-term clinical outcomes are achieved after intra-articular MSC 
delivery remains controversial and thus systems to overcome this limitation have been 
extensively studied.  
In order to use MSCs to treat FODs, it is imperative to confirm that preparations 
of MSCs are capable of undergoing transformation into cartilage (chondrogenesis) and 
to mechanistically define this process. The micromass pellet system was performed by 
Sekiya et al. as described in Johnstone et al. for human MSCs from bone marrow 
aspirates (Johnstone et al., 1998; Sekiya et al., 2002). Briefly, MSCs are trypsinized, 
counted and cell aliquots are spun down at 500xG in 15 mL polypropylene conical tubes 
and cultured for up to 21 days (Johnstone et al., 1998). This system is unique as it 
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represents a 3D assay and the fetal bovine serum (FBS) containing medium is replaced 
with a serum free medium. This method has been utilized to evaluate chondrogenesis in 
equine and canine MSC studies (Kisiel et al., 2012; Vidal et al., 2008). Unfortunately, 
Kisiel et al., was unable to differentiate MSCs into chondrocytes using the protocol 
described by Vidal et al. and their attempt resulted in central necrosis and 
undifferentiated cells on histopathology (Kisiel et al., 2012). Using human MSCs, 
similar findings of central necrosis (Liangming Zhang et al., 2010) have occurred with 
the additional finding that only the outside layer of the pellets underwent chondrogenesis 
(Mueller and Tuan, 2008; Murdoch et al., 2007).  
Kisiel et al., also noted that a proteoglycan matrix could be present in spite of the 
undifferentiated cells as the pellets stained with Alcian blue stain. Without supportive 
results on H&E and Safranin O staining however, it is difficult to form a conclusive 
statement on whether the matrix was present (Kisiel et al., 2012). Thus, mRNA 
expression of chondrocyte markers would be useful to confirm or deny differentiation of 
the MSCs down the chondrogenic lineage.  
In addition to the concerns described above, traditional micromass pellet cultures 
are extremely small (1 mm – 3 mm diameter) in size depending on the species and 
induction recipe utilized (Shirasawa et al., 2006). Thus, using these cultures in 
translational studies is not feasible due to the inability to provide sufficient quantity of 
reparative cultures (Grande et al., 1999). Unpublished observations from our laboratory 
have also suggested that attempting to induce chondrogenesis of canine MSCs using the 
traditional/classic micromass pellet method is often unsuccessful. When canine MSCs 
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are placed in control culture medium with fetal bovine serum (CCM), the canine MSCs 
do not maintain micromass aggregates and undergo apoptosis. Given the fact that the 
long-term goal of regenerative medicine is to develop clinically relevant treatment 
options, chondrogenic cultures need to be large enough to fill in vivo defects in humans 
and veterinary species, and the histologic characteristics of these pellets must be 
improved. Tissue engineering is a sub-specialty of regenerative medicine that is 
attempting to address these limitations.  
 
TISSUE ENGINEERING 
Tissue engineering is a sub-specialty of regenerative medicine in which 
regenerative cells (i.e. MSCs) are combined with specialized scaffolds and/or growth 
factors to repair, regenerate and/or improve the structure and function of diseased tissue 
(Lijie Zhang et al., 2009). Focusing on tissue engineering constructs that combine cells, 
growth factors and a scaffold, both biologic and synthetic scaffolds with reparative cells 
such as chondrocytes or mesenchymal stem cells (MSCs) have been examined (Martin et 
al., 2001; Neu et al., 2009; Zscharnack et al., 2010). Ideally a scaffold should include the 
following characteristics: three dimensional, porous with an interconnected pore 
network, biocompatible, predictably bioresorbable, suitable for cell attachment, 
proliferation and differentiation, and lastly scaffolds must possess mechanical properties 
approaching those of the tissues to be replaced (Hutmacher, 2000). Using these 
scaffolds, MSCs, osteoblasts and chondrocytes can be harvested from the patient’s 
tissues and expanded in vitro. Scaffold materials such as: hydroxyapatite, poly(-
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hydroxyesters) and natural polymers such as collagen and chitin have been described 
(Gunatillake and Adhikari, 2003; Guo and Ma, 2014). 
Unfortunately, substantial limitations exist with current articular cartilage tissue 
engineering scaffolds. First, the ability of the scaffold to adhere to the surrounding native 
cartilage when placed within a defect has not been refined. Small defects have been 
repaired using a press-fit system however, larger lesions (as present in vivo) of 1 cm 
diameter are often not amenable to this repair (Grande et al., 1999). Without the ability 
to bond and integrate with adjacent tissues, tissue engineering scaffolds placed within 
the lesion are unable to remain in position to obtain a long-term biologic interlock. 
Second, current tissue engineering constructs provide an incomplete restoration of 
normal tissue architecture. Long term follow-up of cartilage tissue engineering 
constructs composed of polyglycolic acid (PGA) placed in a rabbit model illustrated that 
centers of calcification formed within the upper zones of the construct (Kandel et al., 
1997). The authors concluded that in order to achieve long-term clinical success, current 
constructs must more closely resemble normal articular cartilage in regards to histologic 
appearance and biomechanical function. Biomechanical function is an important 
characteristic of a cartilage tissue engineering construct fundamental to in vivo success. 
A study by Neu et al., used magnetic resonance imaging (MRI) to look at the 
biomechanics of cartilage constructs when placed under mechanical stress. This study 
illustrated that mechanical stress is not distributed equally between the repair and the 
surrounding tissue and thus further integration strategies are necessary (Neu et al., 2009). 
Unless the above limitations are addressed, disease progression is likely to continue even 
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with construct implantation. Furthermore, development of consistent cartilage tissue-
engineering constructs capable of treating cartilage lesions is not only important for 
human patients, but may prove essential in veterinary patients as their clinical 
presentation is often delayed compared to their human counterparts (thus disease is often 
progressed) (Breur and Lambrechts, 2012). Despite the limitations of previous attempts 
at cartilage tissue engineering, the benefits of cartilage tissue engineering far outweigh 
current limitations.  For this reason, cartilage tissue engineering efforts continue.  
 
COLLAGEN AS A SCAFFOLD 
Collagen is the most abundant protein in the extracellular matrix. Collagens are 
structural proteins composed of three independent left-handed polypeptide -chains 
(Pietz, 1984) creating a unique right-handed triple helix (Gelse et al., 2003). Collagen is 
most commonly synthesized by fibroblasts by transcribing genes in the nucleus for 
mRNA processing; after splicing it is transported to the rough endoplasmic reticulum 
(rER) and golgi complex. Here the triple helix structure is formed from individual -
chains (Gelse et al., 2003). Each triple helix contains an integral repeat of amino acid 
motifs, Glycine-X-Y (GXY), enabling for the rotating helical structure around the 
central glycine axis (Hofmann et al., 1978). Glycine is the pivotal amino acid because of 
its size and repetitive location in the sequence allowing for bulkier side chains on the 
periphery. While glycine is necessary in the first position the subsequent amino acids, X 
and Y, can be any other sequence, but these positions are most commonly occupied by 
proline and hydroxyproline (Gelse et al., 2003). After post-translational modification, 
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chains may be assembled as homotrimers (collagen types: II, III, VII, and X) or as 
heterotrimers (collagen types: I, IV, V, VI, IX, and XI) before secretion as pro-collagen 
into the extracellular space (Gelse et al., 2003). Once secreted specific members of 
metalloproteinase family, procollagen N- and C- proteinase, cleave the N- and C-
terminals, respectively (Prockop et al., 1998). Afterwards, collagen fibrils spontaneously 
assemble through hydrophobic and electrostatic interactions creating staggered 
arrangements of monomers, which aggregate to fibrils, and eventual fibrous tissue 
(Nimni, 1988; Silver et al., 1992). 
In addition to the maintenance of structural integrity of tissues and organs, the 
extracellular matrix serves an important role in providing instruction through 
biomechanical and biochemical cues. Usually cells establish an extracellular matrix 
strength to fit the need of that specific cell during development and tend to maintain that 
strength over a lifetime (Humphrey et al., 2014). However, in diseased conditions this 
matrix can render the extracellular matrix more compliant and cause increases in stress 
and strain (Humphrey et al., 2014). A feedback mechanism then causes increased 
extracellular matrix stiffening, often referred to as fibrosis, mechanical failure or other 
pathologies (Humphrey et al., 2014). 
While true that the composition of articular cartilage is composed of collagen 
type II, collagen type I scaffolds are commonly used for tissue engineering. Collagen 
type I is frequently used due to its abundance, availability and biocompatibility 
(Glowacki and Mizuno, 2008). Canine chondrocytes were placed in collagen type I and 
collagen type II scaffolds to be investigated in vitro however, and results favored using a 
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collagen type II scaffold (Nehrer et al., 1997). Unfortunately, in our experience collagen 
type II has been quite difficult to obtain in reliable formats, particularly in the quantities 
required for articular cartilage tissue engineering. Using hMSCs, Yokoyama et al., 
combined collagen type I with human synovium MSCs and found that a combination of 
5 x 107 to 1 x 108 MSCs combined with 30 mg/mL collagen type I produced constructs 
which illustrated increased mRNA expression of COL2A1 indicating progressive 
differentiation of cartilage with expression of aggrecan, decorin and biglycan 
(Yokoyama et al., 2005).  With regards to animal models, Zscharnack et al., utilized 
collagen type I gel combined with ovine MSCs or pre-differentiated chondrocytes to 
create a construct capable of integrating into two osteochondral defects with a diameter 
of 7 mm and a depth of 2 mm (Zscharnack et al., 2010). This study determined that 
constructs in which pre-differentiated chondrocytes were combined with collagen type I 
lead to an improved histologic appearance with regards to surface integrity, adhesion to 
adjacent cartilage, hypocellularity and mineralization when compared to constructs with 
undifferentiated MSCs and control groups (Zscharnack et al., 2010). Even when using 
collagen type I scaffolds, integration into surrounding tissues still occurred. 
GROWTH FACTORS 
Growth factors that promote chondrogenesis have been extensively studied for decades 
in humans however, canine research is still in its infancy (Figure 1.1). According to the 
reference Mesenchymal Stem Cells Methods and Protocols, an effective medium for 
inducing chondrogenesis in human MSCs includes: high glucose DMEM, 50 g/mL of 
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L-ascorbic-2-phosphate, 40 g/mL of L-proline, 100 g/mL of sodium pyruvate, 5 mL 
ITS+ Culture Supplement (6.25 g/mL insulin, 6.25 g/mL transferrin, 6.25 ng/mL 
selenous acid, 1.25 mg/mL bovine serum albumin, 5.35 mg/mL linoleic acid) (Reger et 
al., 2008). The specific cytokines/growth factors added immediately prior to use to this 
solution for chondrogenic differentiation include 10 ng/mL rhTGF-3, 10-7 M 
dexamethasone and 500 ng/mL rhBMP-2 (Reger et al., 2008). Prior to the publication by 
Reger et al., many publications by multiple investigators helped to define the induction 
medium detailed above (Martin et al., 2001; Puetzer et al., 2010; Sekiya et al., 2002; 
2001; 2005; Shintani and Hunziker, 2011; Yokoyama et al., 2005). With respect to the 
optimum combination of growth factors that induce maximal chondrogenic 
differentiation of canine MSCs, less research has been conducted. A study by Shirasawa 
et al., determined that the combination of 100 nM dexamethasone, 500 ng/mL BMP-2 
and 10 ng/mL TGF-3 was optimum for chondrogenic differentiation using hMCSs 
(Shirasawa et al., 2006). This combination was compared with 1) TGF-3 and 
dexamethasone alone, 2) TGF-3, dexamethasone and retinoic acid, 3) TGF-3, 
dexamethasone, insulin growth factor 1, 4) TGF-3, dexamethasone, bFGF2, and 5) 
TGF-3, dexamethasone and insulin (Shirasawa et al., 2006). In addition to producing 
the most chondrogenic cultures as assessed by histology, the combination of TGF-3, 
dexamethasone and BMP-2 produced the largest diameter cultures after 21 days of 























Figure 1.1:  PubMed literature search for primary research articles focused on chondrogenesis in 
human beings versus canines.  Using the search terms “human”, “chondrogenesis”, and “mesenchymal 
stem cells”, 1478 articles were identified demonstrating the robust foundation of literature that exists 
on the subject of human MSC chondrogenesis. In contrast, using the search terms “canine”, 
“chondrogenesis”, and “mesenchymal stem cells”, only 30 articles were identified.  Further screening 
of this list of publications resulted in identification of 4 publications that attempted to perform 
chondrogenesis with canine MSCs using the traditional micromass assay.  This literature search 





Dexamethasone is a glucocorticoid that is used commonly in MSC cultures for 
adipogenic, osteogenic and chondrogenic differentiation (Derfoul et al., 2006; Sekiya et 
al., 2002; Shintani and Hunziker, 2011; Shirasawa et al., 2006; Yokoyama et al., 2005). 
Although required for multipotent differentiation, the exact mechanism of action is 
unknown (Derfoul et al., 2006).  
Interestingly, Shintani et al., demonstrated that dexamethasone suppresses the 
effect of BMP-2 almost completely and had little impact on the effect of TGF-1 during 
chondrogenic differentiation of synovial explants (Shintani and Hunziker, 2011). 
Furthermore, when dexamethasone was added to aggregates of isolated synovial MSCs 
instead of synovial explants, it had no influence on either the TGF-1 or BMP-2 thus 
indicating the importance of the microenvironment to which dexamethasone is added 
(Shintani and Hunziker, 2011). In contrast to the findings on synovial implants, 
dexamethasone was added to bone marrow derived MSC aggregates and was shown to 
greatly enhance chondrogenesis induced by TGF-1 (Shintani and Hunziker, 2011). This 
effect is consistent with other previously reported studies (Derfoul et al., 2006; 
Johnstone et al., 1998). This research not only demonstrates the importance of 
dexamethasone and various growth factor combinations in chondrogenesis of MSCs, but 
further indicates the importance of the origin of the MSCs when considering their 
interaction with various growth factors. 
Transforming growth factor  (TGF-) is a member of the transforming growth 
factor- superfamily which also includes bone morphogenetic proteins and activins. 
TGF- is produced and recognized by almost every cell in the body, regulates the 
 
 22 
proliferation and differentiation of cells and is involved in embryonic development, 
wound healing and angiogenesis (Blobe et al., 2000). Three isoforms of TGF- exist in 
vertebrates: TGF-1, TGF-2 and TGF-3. TGF-1 is expressed in endothelial, 
hematopoietic and connective tissue, TGF-2 is expressed in epithelial and neuronal 
cells and TGF-3 is expressed in mesenchymal cells (Blobe et al., 2000). Most 
chondrogenic differentiation studies have focused their efforts on TGF-1 or TGF-3 
(Derfoul et al., 2006; Reger et al., 2008; Sekiya et al., 2005; 2002; 2001; Shintani and 
Hunziker, 2011; Yokoyama et al., 2005). In order to differentiate between the three 
isoforms, Barry et al., directly compared the addition of TGF-1, TGF-2 and TGF-3 
to chondrogenic pellets (Barry et al., 2001). This specific experiment examined 
chondrogenic differentiation of human MSCs. Interestingly, TGF-3 and TGF-2 pellets 
accumulated significantly more glycosaminoglycans when compared to TGF-1. 
Additionally, with regards to differentiation to a chondrocytic phenotype on histologic 
examination, TGF-1 consistently produced inferior collagen type II staining. Thus, 
although previous studies have shown chondrogenic differentiation using TGF-1, TGF-
3 may produce higher quality chondrogenic pellets for future clinical use.  
Bone morphogenetic proteins (BMPs) are members of the transforming growth 
factor- superfamily with the exception of BMP-1 (Wozney et al., 1988). The structure 
of the TGF- superfamily members include an amino-terminal signal sequence, a pro-
domain and their carboxy-terminal mature peptide which is released by furin-mediated 
cleavage (Dijke et al., 2003). The mature domain is characterized by a 7-cysteine motif 
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and forms homodimers and heterodimers which are covalently linked by one di-sulphide 
bond (Dijke et al., 2003). BMP has the ability not only to induce bone by stimulating 
differentiation into the osteoblast lineage, but it also inhibits differentiation toward 
myoblasts (Katagiri et al., 1994). Further studies have also demonstrated the role of 
BMP in the development and function of pulmonary, cardiovascular, reproductive, 
urogenital organs and the nervous system (H. Chang et al., 2002; Goumans and 
Mummery, 2002). 
With regards to mechanism of action, BMPs bind to specific serine/threonine 
kinase receptors (type I and type II) (Kawabata et al., 1998; Massagué, 1998). Once the 
receptor is bound, intracellular signaling via phosphorylation of specific proteins, 
including the Smad proteins, occurs (Kawabata et al., 1998; Massagué, 1998). BMP 
receptors phosphorylate Smad1, Smad5, and Smad8. R-Smad/Smad4 complexes are 
formed by activation by type-I receptors. These complexes accumulate in the nucleus 
where they regulate target genes (Kawabata et al., 1998; Massagué, 1998). Direct 
binding of R-Smads and Co-Smads to DNA is by MH1 domains and BMP-specific R-
Smads interact with GC-rich containing sequences (Ishida et al., 2000; Korchynskyi and 
Dijke, 2002). 
More importantly, mice genetically deficient in BMP transcription factor targets 
such as: Runx2, Dlx5, osterix and Msx2 develop skeletal abnormalities (Korchynskyi et 
al., 2004). The induction of Id proteins, inhibitors of basic helix-loop-helix proteins 
(Korchynskyi and Dijke, 2002) by BMPs may block the differentiation of mesenchymal 
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stem cells toward adipocytes and myoblast and thus support osteoblast differentiation 
(Dijke et al., 2003).  
In addition to promoting osteogenic induction, BMPs have the ability to induce 
endochondral ossification and chondrogenesis (Leboy et al., 2001). The effect of BMP in 
chondrogenesis appears to be mediated by Sox 9 which is important to chondrogenesis 
and the fabrication of collagen type II and X (Semba et al., 2000). BMPs also affect Ihh, 
Sonic hedgehog (Shh) and Desert hedgehog (Dhh). Ihh and Shh enhance chondrogenesis 
and endochondral ossification (Grimsrud et al., 2001; Krishnan et al., 2001). It is 
important to realize however, that other effects of Ihh/Shh on cartilage are independent 
of BMPs. Ihh/Shh induces Nkx3.2, which induces Sox 9 which, in the presence of BMP 
induces chondrogenesis (Murtaugh et al., 2001; Zeng et al., 2002). In the presence of 
BMP, Sox 9 and Nkx3.2 establish a positive feedback loop to initiate chondrogenesis 
(Zeng et al., 2002).          
Specifically, BMP-2 has been shown to enhance chondrogenesis using human iPS 
cells using qPCR expression analysis of Sox9, Col2a1, aggrecan, Col2b, Runx2, 
collagen type I and ColXa1 on cell micromasses (Guzzo et al., 2013). Additionally, in 
one study, BMP-2 increased collagen type II expression under leptin stimulation and 
suggested that BMP-2 may help repair damaged tissues undergoing OA in obese 
individuals (Chang et al., 2015). Based on this work, BMP-2 has been recognized as an 
important growth factor for chondrogenesis in humans and may be beneficial when 
translating these methods to canine chondrogenesis.  
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In addition to BMP-2 and TGF-3,  bFGF has been specifically implicated in 
increasing the proliferation rate of chondrocytes (Solchaga et al., 2005). The exact 
mechanism as to how this occurs is not fully understood however, it has been shown that 
bFGF downregulates a large percentage of known positive and negative regulators of 
proliferation (Solchaga et al., 2005). Even with this downregulation, the ultimate 
outcome of bFGF on human cells is increased proliferation. Furthermore, the gene 
expression profile performed in this study suggests that bFGF regulates chondrogenic 
differentiation through MAPK and Wnt signaling. With regards to MAPK, bFGF 
upregulates DUSP 4 and 6 which are negative regulators of the MAPK pathway, and 
thus, bFGF promotes chondrogenic differentiation (Solchaga et al., 2005). Similarly, 
bFGF downregulates signaling in the Wnt pathway which has been linked to the MAPK 
pathway (Tufan et al., 2002; Tuli et al., 2003) and is important for chondrogenesis and 
development in general (Solchaga et al., 2005). Alternatively, in a similar study in 
horses, bFGF did not compromise chondrogenesis, however, it did significantly 
accelerate synovial fluid chondroprogenitor cell expansion (Bianchessi et al., 2016). The 
above evidence combined with other work from our lab (WB et al., 2017), indicate that 
bFGF may be beneficial to chondrogenesis and should be examined during initial 
evaluation of canine chondrogenesis. 
 
PURPOSE 
The long-term goal of the lab is to mechanistically define the process of canine 
chondrogenesis and to develop a viable tissue engineering construct capable of restoring 
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normal joint structure and function for the treatment of FODs in veterinary and human 
patients. As a first step toward that goal, this thesis describes the development of an 
improved in vitro system to perform chondrogenic differentiation assays with canine 
MSCs.  Secondly, we describe the use of this system to evaluate the effect of the growth 
factors/cytokines dexamethasone, TGF-3, BMP-2, and bFGF on chondrogenesis of 
canine bone marrow-derived MSCs. This work is of clinical significance as once a 
combination of growth factors that consistently promote chondrogenesis is determined 






CHAPTER II  
DEVELOPMENT OF AN IMPROVED CHONDROGENIC DIFFERENTIATION 
ASSAY AND ASSESSMENT OF GROWTH FACTOR COMBINATIONS ON 
CANINE MESENCHYMAL STEM CELL (MSC) CHONDROGENESIS  
 
SUMMARY 
Degenerative and developmental joint disorders affect millions of human beings 
and veterinary species resulting in chronic pain, immobility, and loss of economic and 
personal productivity. Due to the fact that articular cartilage does not readily heal, 
attempts at treating articular cartilage lesions either medically or surgically are often met 
with frustration. The dog is an excellent translational model for humans affected by focal 
osteochondral defects (FOD) allowing scientists to evaluate feasibility, safety and 
efficacy of novel treatment strategies for subsequent translation into human beings 
(Hoffman and Dow, 2016). Much effort has focused on using mesenchymal stem cells 
(MSCs) to develop tissue engineering constructs to treat FODs.  Chondrogenesis, or the 
differentiation process by which MSCs transition to chondrocytes, has been refined for 
decades in human beings. In contrast, our understanding of the chondrogenic process of 
canine mesenchymal stem cells (cMSCs) is in its infancy. A barrier to understanding the 
mechanistic processes governing canine chondrogenesis is the current inability to 
consistently induce chondrogenesis in vitro using protocols effective for human MSCs 
(hMSCs). Previous work using hMSCs has demonstrated that dexamethasone, TGF-3 
and BMP-2 are the optimal growth factors involved in influencing hMSCs down the 
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chondrogenic lineage. Recently, it was discovered that the addition of bFGF was 
necessary for cMSC invasion using 3D collagen type I invasion assays. Thus, the 
objectives of this study were to: first develop an improved in vitro assay to induce 
chondrogenesis of cMSCs; and, second to evaluate the effects of dexamethasone (D), 
TGF-3 (T), BMP-2 (B), and bFGF (F) on cMSC chondrogenesis using the improved 
assay. Based on our laboratories substantial experience with serum-free three-
dimensional (3D) collagen type I assays and existing literature on chondrogenesis of 
human and ovine MSCs in collagen type I scaffolds, we hypothesized that the inclusion 
of bFGF in chondrogenic differentiation medium would result in improved 
chondrogenesis when compared to media containing dexamethasone, and various 
combinations of TGF-3 and BMP-2.  
In phase 1, cMSCs were suspended in 5 mg/ml collagen type I gels in a serum-
free environment with different combinations of these growth factors at two 
concentrations. Chondrogenic media was added to the cultures. Cultures were incubated 
for 21 days and evaluated with morphometry, live/dead staining, and with 
histopathology. Using the results of phase 1, four growth factor combinations were 
selected to be further assessed for chondrogenesis using quantitative assessment 
measures. In phase 2, cultures were established as for phase 1 and again cultured for 21 
days. Cultures were evaluated for early cytotoxicity and apoptosis using a Lactate 
Dehydrogenase (LDH) assay, glycosaminoglycan (GAG) content using a colorimetric 
GAG assay, and the expression of chondrogenic and osteogenic genes using quantitative 
(real-time) PCR (qPCR). Cultures provided with high concentrations of BMP-2 and 
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bFGF were larger, heavier, and demonstrated more uniform gross appearance. The 
combination of DTBF resulted in reduced stress in early stages of culture as assessed by 
LDH levels in conditioned media. When glycosaminoglycan levels were quantified, 
cultures containing DTBF and DTB media exhibited significantly higher GAG levels as 
compared to other treatment groups. Interestingly, both osteogenic and chondrogenic 
gene expression significantly increased over the 21 day time course. Histologically, 
cultures treated with DTB and DTBF exhibited focal areas of primitive mesenchymal 
cells organizing into chondrogenic arrangements. These areas stained positive for 
proteoglycan using Toluidine blue and Safranin O.  
Overall, the 3D collagen type I serum-free system consistently allowed 
chondrogenic assessment of cMSCs and both subjective and quantitative assays revealed 
important differences in the various treatment groups.  Cultures treated with media 
containing DTB and DTBF appear to be the most promising for inducing 
chondrogenesis of canine bone marrow MSCs.  This work serves as an initial, important 
advance in the field of canine chondrogenesis and regenerative medicine for treatment of 
articular cartilage injuries. 
 
INTRODUCTION 
Osteochondrosis and traumatic joint diseases, such as osteochondrosis (OC), 
osteochondritis dissicans (OCD) and traumatic focal osteochondral defects (FODs), are 
articular cartilage lesions leading to osteoarthritis (OA) in millions of human and 
veterinary species. Broadly, the two primary categories of osteoarthritis treatment 
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include medical and surgical management. While medical management is often used to 
treat patients with early FODs, management is often life long and requires the addition 
of new treatments and drugs over time. When medical management fails to alleviate 
symptoms, surgical treatments are often pursued. Surgical treatment options for FODs 
can be divided into palliative and restorative treatments. Palliative treatments attempt to 
remove the source of irritation/inflammation enhancing the formation of fibrocartilage 
over the defect. This is accomplished through procedures such as: debridement, abrasion 
arthroplasty and microfracture. Restorative treatments aim to repair or replace the 
cartilage defect in order to fully restore structure and function (Cole et al., 2009). This is 
accomplished through procedures such as: autologous osteochondral transplants 
(OATS), autologous chondrocyte implantation (ACI), or placement of allogenic 
osteochondral tissue grafts or synthetic cartilage substitutes (Arinzeh et al., 2003; 
Breinan et al., 2001; Cook et al., 2008; Freed et al., 1993). Although restorative 
treatments are performed in both human and veterinary medicine, they are not without 
complication, including donor site morbidity (Feczkó et al., 2003; Reddy et al., 2007; 
Szerb et al., 2005a), cartilage thickness discrepancies (Breur and Lambrechts, 2012), 
poor graft survival and progression of OA (Breur and Lambrechts, 2012). In order to 
navigate these obstacles, recent work has focused the ability of regenerative medicine to 
restore the structure and function for FOD lesions. 
Regenerative medicine is defined as an interdisciplinary field of research and 
clinical application focused on the repair, replacement or regeneration of cells, tissues or 
organs to restore impaired function resulting from any cause, including congenital 
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defects, disease, trauma and aging (Daar and Greenwood, 2007). The direct injection of 
mesenchymal stem cells (MSCs) is one method by which regenerative medicine may be 
used to treat FODs. Unfortunately, studies have shown that few cells remain at the 
injection site after delivery (Krause et al., 2010). To address these limitations, tissue 
engineering, a sub-specialty of regenerative medicine in which MSCs are combined with 
scaffolds and/or growth factors, has been extensively studied. The goal of this treatment 
is to repair, regenerate and/or improve the structure and function of diseased articular 
cartilage (Lijie Zhang et al., 2009). Unfortunately, even tissue engineering as a treatment 
option has substantial limitations that exist including: the ability of the scaffold to 
integrate with surrounding native bone and cartilage (Grande et al., 1999), failure to 
provide complete restoration of normal tissue architecture (Kandel et al., 1997), an 
inability to restore the biomechanical properties of native cartilage (Neu et al., 2009) and 
the lack of knowledge of the ideal chondrogenic media that would contribute to the 
production of cartilage-like tissue engineering constructs.  
Although culture conditions resulting in consistent chondrogenesis of human 
MSCs (hMSC) have been known for decades, the ideal chondrogenesis medium remains 
unknown for canine MSCs (cMSCs) (Kisiel et al., 2012). As detailed in Chapter I, bFGF 
has been implicated in increasing the proliferation rate of chondrocytes (Solchaga et al., 
2005) and inclusion of bFGF in expansion medium has resulted in increased 
chondrogenic culture size and proteoglycan content (Solchaga et al., 2005). 
Interestingly, bFGF has also been shown to improve cMSC survival, attachment and 










Figure 2.1: Basic fibroblast growth factor (bFGF) is an important survival factor for the invasion of cMSCs in 
3D collagen matrices. In a related study in our laboratory, P2 marrow cMSCs were suspended on 3.75 mg/ml 
collagen type I gels under serum-free conditions and assessed for invasion over a 48 hour time course. A) 
Quantification of cell invasion. The invasion agonist mixed within the collagen gels is provided on the top row of 
the table, while supplemental growth factors added to culture media are listed in the left hand column.  Number 
of invading cells (mean +/- SD) are reported per high powered field (n= 3 wells/condition).  Note the effect of 
bFGF on overall cell invasion, regardless of the agonist mixed within the collagen gels. B) Graphic illustration of 
the 3D cMSC invasion assay in which control gels remain untreated with invasion agonists (top) whereas 
invasion agonists of interest (in this experiment PDGF-BB) are polymerized within the gel (bottom).  Cells 
proteolytically invade the collagen matrices in response to relevant agonists.  A side view of cMSC invasion 
cultures is provided demonstrating the appearance of cMSC invasion in response to PDGF-BB (agonist in gel) 




Thus, given our lab’s long term goal of developing viable tissue engineering 
constructs capable of restoring normal joint structure and function, the objectives of this  
study were to: first develop an improved in vitro assay to induce chondrogenesis of 
cMSCs; and, second to evaluate the effects of dexamethasone (D), TGF-3 (T), BMP-2 
(B), and bFGF (F) on cMSC chondrogenesis using the improved assay. Based on our 
laboratories substantial experience with serum-free three-dimensional (3D) collagen type 
I assays and existing literature on chondrogenesis of human and ovine MSCs in collagen 
type I scaffolds, we hypothesized that inclusion of bFGF in chondrogenic differentiation 
medium would result in improved chondrogenesis when compared to media containing 
dexamethasone, and various combinations of TGF-3 and BMP-2.  
 
MATERIALS AND METHODS 
Cell culture  
Canine MSCs (cMSCs) were isolated, from the iliac crest of an adult Walker 
Hound as a component of an unrelated study (TAMU AUP 2011-149). Cells were 
confirmed to meet criteria for MSCs as defined by the position paper by Dominici et al 
(Dominici et al., 2006). This included morphological assessment, colony forming 
capacity, flow cytometry profile, and in vitro tri-lineage differentiation (Figure 2.2). 
Cells were cryopreserved in 30% FBS (PS-FBS: Atlanta Biological, Inc., Flowery 
Branch, GA) and 5% DMSO (Sigma, St. Louis, MO) and stored in liquid nitrogen. 
Passage 1 (P1) cMSCs (1 x 106 total cells) were thawed, plated overnight into two 150 



















Figure 2.2: Characterization of canine bone marrow-derived mesenchymal stem cells (cMSCs). 
Bone marrow cMSCs were isolated using gradient centrifugation and adherence to tissue culture 
plastic. P1 cells were expanded at 100 cells/cm2 and cryopreserved in 5% DMSO and 30% FBS. 
Cells were thawed and expanded to P2 cells for subsequent experiments. A) Phase contrast 
microscopy image of cMSCs in culture. B) cMSC colony forming unit (CFU) assay from the 
primary cell population (bone marrow aspirate) demonstrating the presence of CFUs within the 
nucleated fraction of bone marrow. C) 21 day Alizarin Red Staining (ARS) of osteogenic cMSCs. 
D) 21 day Oil Red O staining of adipogenic cMSCs. E) A gross photograph of a 21 day 
chondrogenic micromass culture. F) Micromass cultures from (E) were fixed, sectioned, and 
stained with Toluidine blue to screen for proteoglycan deposition. G) cMSC demonstrated flow 




µg/mL streptomycin, 0.292 mg/mL glutamate (Invitrogen, Carlsbad, CA) and 10% 
premium select fetal bovine serum (PS-FBS: Atlanta Biological, Inc., Flowery Branch, 
GA)) at 37°C and 5% humidified CO2.  The following day cells were washed with PBS, 
trypsinized, and re-plated as P2 cells for expansion at 250 cells/cm2.  Cells were 
incubated as noted above with media changes occurring every other day until cells 
reached 70% confluence. Prior to each experiment, P2 cMSCs were washed with PBS, 
trypsinized, and centrifuged at 500xG for 5 minutes. Cells were washed in an additional 
10 mL volume of Dulbecco’s Modified Eagle Medium (DMEM) in an effort to remove 
residual serum from the medium. Cells were manually counted via hemocytometer.  
Collagen type I isolation  
Collagen type I was prepared from commercially acquired rat tail tendons by 
non-proteolytic isolation using 0.1% acetic acid (Bayless et al., 2009; Rajan et al., 2006). 
After lyophylization, collagen type I was re-suspended at 7.1 mg/mL and maintained at 
4°C. 
Suspension of cMSCs in 3D collagen type I gels 
cMSCs were combined at 10 x 106 cells/mL into a collagen type I gel (5 mg/mL 
final collagen type I concentration) and maintained at 4°C as previously described 
(Salazar et al., 1999). The cell and gel mixture was divided into the treatment groups 
noted in Figure 2.3 for phase 1. TGF-3 (rhTGF-3, R&D Systems, Minneapolis, MN) 












Figure 2.3: Phase 1 experimental approach. In order to screen a large number of growth factor doses and 
combinations, an initial set of experiments was performed with cMSCs suspended in 3D collagen type I gels. In 
these experiments, the concentrations of dexamethasone (10-7 M) and rhTGF-3 (10 ng/mL) remained constant. 
Recombinant human BMP-2 (rhBMP-2) was supplemented at 0 ng/mL (No BMP-2), 50 ng/mL (Low BMP-2) or 
500 ng/mL (High BMP-2). Recombinant human basic fibroblast growth factor (rhbFGF) was supplemented at 0 
ng/mL (No bFGF), 10 ng/mL (Low bFGF) or 100 ng/mL (High bFGF). Cultures were thus treated with ten 
varying media conditions for 21 days and evaluated subjectively using live/dead staining, gross photography and 
assessment of culture weight, and histopathology. Results of Phase 1 studies were used to select the most 




and a high dose (500 ng/mL) of BMP-2 (rhBMP-2; R&D Systems), with a low 
(10 ng/mL) and a high (100 ng/mL) dose of bFGF (rhbFGF, R&D Systems) and the 
combination of a low and a high dose of BMP-2 with a low and a high dose of bFGF. 
Once the cell, collagen type I gel, and growth factor combinations were manually 
pipetted, 100 µL of the cMSC/collagen gel mixture was pipetted into individual wells of 
a 24 well plate. The plate was then placed in the incubator at 37°C and 5% humidified 
CO2 for 30 minutes to allow the collagen to gel (i.e. to set or solidify). Next, 750 µL of 
chondrogenic medium was added to each well. This chondrogenic medium consisted of 
DMEM containing 100 units/mL of penicillin, 100 µg/mL of streptomycin, 10-7 M 
dexamethasone, 50 µg/mL ascorbate-2-phosphate (Sigma), 40 µg/mL L-proline (Sigma), 
100 µg/mL sodium pyruvate (Sigma) and 10 ng/mL TGF-3 (R&D Systems) added as 
described (Reger et al., 2008; Sekiya et al., 2002). Media were also supplemented with 
BMP-2 and bFGF as noted in Figure 2.3. Once all pellets were covered in chondrogenic 
medium, they were incubated for up to 21 days with media changes performed twice 
weekly. Cultures were photographed and weighed at day 3 and day 21. At 21 days, 
cultures were fixed in 10% neutral buffered formalin, embedded in paraffin, and 
sectioned for histologic evaluation using H&E, Toluidine blue and Safranin O.  
The same protocol was followed for phase 2 using four combinations of growth 
factors (Figure 2.4). 
Subjective assessment of viability in early cMSC cultures using live/dead staining 









Figure 2.4: Phase 2 experimental approach. Based on the results of Phase 1 studies, four promising growth 
factor combinations were selected for quantitative analysis. As with Phase 1 studies, the concentrations of 
dexamethasone (10-7 M) and rhTGF-3 (10 ng/mL) remained constant. Recombinant human BMP-2 (rhBMP-2) 
was omitted from culture medium (No BMP-2), resulting in the treatment referred to as DT.  BMP-2 was 
supplemented at 500 ng/mL (High BMP-2) resulting in the treatment group DTB. Recombinant human basic 
fibroblast growth factor (rhbFGF) was either then omitted from culture medium (No bFGF) or added to culture 
medium at 100 ng/mL (High bFGF), resulting in the treatment groups DTF and DTBF respectively. Cultures 
were thus treated with 4 media conditions for 21 days and quantitatively assessed using the Lactate 
Dehydrogenase (LDH) assay, quantitative glycosaminoglycan (GAG) assay, and qPCR for transcriptional 




washes performed. After the final PBS wash, 500 µL of fresh PBS containing 0.2 µM 
calcein (Sigma) and 100 µg/mL propidium iodide (Botinium, Hawyard, CA) were added 
to each construct (n=3 constructs/treatment condition). Constructs were incubated at 
37°C for 30 minutes and evaluated for live/dead staining using an Olympus microscope 
and fluorescent microscopy. Individual fluorophore images were acquired. 
Subsequently, images were merged and overlays produced using SPOT software 
(version 5.1; Sterling Heights MI). 
Quantitative assessment of cytotoxicity/apoptosis with the Lactate Dehydrogenase 
(LDH) assay 
As noted above, 3D constructs containing collagen type I and P2 cMSCs were 
cultured for either 24- or 72 hours with media exchange occurring on day 0, day 1 (after 
sample acquisition) and day 3 (after sample acquisition). Conditioned media (n=3) from 
each treatment group were collected in 200 µL aliquots and stored at -20°C. Upon 
completion of all experiments, media were allowed to thaw on ice and assessed for LDH 
levels following manufacturer’s instructions using the colorimetric plate reader assay 
“Determination of Optimum Cell Number for LDH Cytotoxicity Assay kit” 
(ThermoScientific, Rockford, IL).  LDH levels in cultures were quantified against 
known LDH standards and reported as ng/mL LDH in conditioned media.  
Quantitative assessment of Glycosaminoglycan (GAG) content 
3D constructs containing collagen type I and P2 cMSCs were cultured for 3, 10 
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and 21 days to assess glycosaminoglycan content.  At each time point, media were 
removed and n=3 constructs per treatment condition were placed in 500 µL of papain 
solution based on manufacturer’s instructions (Biocolor Life Science Assays, County 
Antrim, UK).  The cultures were heated at 65°C and manually agitated every 15-30 
minutes until the spherical collagen cultures were not visibly identified. Samples were 
then centrifuged at 10,000 RPM for 10 minutes and the supernatant (approximately 500 
µL) collected and stored at -20°C. Upon completion of the experiment, samples were 
allowed to thaw on ice and were assessed for glycosaminoglycan content following 
manufacturer’s instructions for Blyscan Sulfated Glycosaminoglycan Assay (Biocolor 
Life Science Assays, County Antrim, UK) with sample volumes of 30 µL. 
Glycosaminoglycan content levels in cultures were quantified against known 
glycosaminoglycan standards and reported as an amount in ug/mL.  
Assessment of cMSC gene expression using quantitative (q) PCR 
3D constructs containing collagen type I and P2 cMSCs were cultured for 3, 10 
and 21 days to assess gene expression changes over the 21 day time course. At each time 
point, n=6 cultures from each treatment group were incubated at 37°C and 5% 
humidified CO2 in 2.5 mg/mL bacterial collagenase (Sigma) in DMEM for two hours. 
Constructs were manually agitated every 30 minutes until completely dissolved. Once 
dissolved, the digests were centrifuged at 1,000 RPM for 10 minutes to pellet the 
liberated cells. After removal of supernatants, messenger RNA (mRNA) samples were 
isolated using the Dynabeads ® mRNA DirectTM Purification kit (ThermoFisher), treated 
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with DNase to remove any contaminating DNA, and quantified using a Qubit 
Fluorometer 2.0 (ThermoFisher). Complimentary DNA (cDNA) was synthesized from 
30 ng mRNA (normalized across all samples) using random hexamer primers and 
Superscript III reverse transcriptase (Invitrogen) following the SuperScript III RT kit 
instructions. 
Canine qPCR primers for known osteogenic and chondrogenic genes were 
commercially synthesized as follows: Col1A1 (Nicholson et al., 2007) Forward: 
GCCGCTTCACCTACAGTGTCA,  Reverse: GAGGTCTTGGTGGTTTTGTATTCG; 
COL2A (Nicholson et al., 2007) Forward: CAGCAGGTTCACATATACTGTTCTGA, 
Reverse: CGATCATAGTCTTGCCCCACTT; SOX9 (Neupane et al., 2008) Forward: 
GCTCGCAGTACGACTACACTGAC, Reverse: GTTCATGTAGGTGAAGGTGGAG; 
AGGRECAN (Neupane et al., 2008) Forward: ATCAACAGTGCTTACCAAGACA, 
Reverse: ATAACCTCACAGCGATAGATCC; OSTERIX (Neupane et al., 2008) 
Forward: ACGACACTGGGCAAAGCAG, Reverse: 
CATGTCCAGGGAGGTGTAGAC and OSTEOCALCIN (Neupane et al., 2008) 
Forward: GAGGGCAGCGAGGTGGTGAG, Reverse 
TCAGCCAGCTCGTCACAGTTGG. Housekeeping genes RPL13A and RPL32 were 
used and the genes were commercially synthesized as follows: RPL13A (Peters et al., 
2007) Forward: GCCGAAGGTTGTAGTCGT, Reverse: 
GGAGGAAGGCCAGGTAATTC and RPL32 (Peters et al., 2007) Forward: 
TGGTTACAGGAGCAACAAGAAA , Reverse: GCACATCAGCAGCACTTCA 
PCR reactions (20 µL) were prepared with 10 µL of SYBR Green Master Mix 
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(ThermoFisher), 0.6 µL of Forward Primer, 0.6 µL of Reverse Primer, 6.8 µL of water, 
0.4 µL of cDNA, and 1.6 µL of transfer RNA. Cycling conditions were performed using 
the CFX96 Real-Time System (Bio-Rad, Hercules, CA) with an initial SYBR® Green 
PCR Master Mix enzyme activation at 95°C for 10 minutes, followed by 40 cycles of: 
denature at 95°C for 15 seconds, anneal/extend at 60°C for 1 minute. A melt curve was 
performed immediately after qPCR. Cycling conditions were performed at 55°C for 30 
seconds followed by 55°C for 5 seconds. Following this, the temperature was increased 
by 0.5°C per cycle per second for a total of eighty cycles. 
cDNA was used in two independent qPCR reactions measuring the six genes of 
interest using RPL13A and RPL32 as housekeeping genes.  mRNA was also isolated 
from the same cMSCs at day 0 after they were lifted off the expansion plates prior to 
their establishment in a 3D culture. The expression for each gene of interest was 
averaged over the two independent qPCR reactions. The threshold (CT) levels were 
normalized to both the housekeeping genes and the gene expression at day 0 for relative 
gene expression. Relative gene expression was graphed using GraphPad Prism 6.0 
(GraphPad Software, La Jolla, CA). 
Statistical analysis 
Descriptive statistics were generated and presented as mean ± standard deviation 
for all data sets. Analytical statistics included Two-way ANOVA with Tukey’s post-hoc 
test. All statistics were performed with GraphPad Prism 6.0 (GraphPad Software, La 







Gross photographs for cMSC cultures treated with the ten growth factor 
combinations described in Figure 2.3 are shown in Figure 2.5. At day 1 (24 hours after 
initiation of culture), constructs remain somewhat similar in shape and size to their 
appearance immediately upon gel polymerization. By day 3, the majority of cMSC 
constructs underwent a marked condensation event, in which the cell/matrix constructs 
were physically condensed by the cMSCs. Note the consistent size of the no cells 
treatment group at day 1 and day 3, indicating that the condensation event requires the 
presence of cMSC. Interestingly, cultures containing TGF-3 underwent the most 
consistent and dramatic condensation. Cultures treated with serum-free chondrogenic 
basal medium containing dexamethasone alone did not undergo contraction. Control 
constructs treated with 10% FBS also underwent condensation, which is consistent with 
our experience with the use of 10% serum in 3D collagen assays. These results 
demonstrate that cells are required for the condensation of 3D collagen gels, and 
furthermore that the presence of TGF-3 and not dexamethasone alone drives this 
















Figure 2.5: Gross photographs of cMSC/collagen type I constructs at day 1 and day 3.  At the time 
points indicated, culture media were removed, constructs were washed with PBS, and transferred to a 
photography station to document changes in construct size in response to the ten Phase 1 treatment 
conditions. In the absence of cells, collagen type I gels do not experience any notable change in size (left 
construct – No cells). Interestingly, cMSC cultures treated with dexamethasone also failed to undergo 
changes in the size of cultures. In the presence of rhTGF-3 (dashed white line), marked condensation of 
cultures occurs between day 1 and day 3, consistent with what is known about early mesenchymal 
condensation during chondrogenesis and other tissue morphogenesis events.  A cMSC construct treated 
with Complete Culture Medium (CCM) which contains 10% FBS is also provided (second construct from 
left).  This construct also underwent condensation, consistent with prior experience adding FBS to 3D 
collagen cultures. The fact that FBS induced condensation is not surprising as the FBS contains a diverse 











Figure 2.6: Gross photographs of cMSC/collagen type I constructs at day 21. Additional cMSC cultures from 
the experiment shown in Figure 2.3 were incubated for 21 days with media exchange performed twice weekly. 
At that time, constructs were washed with PBS and transferred to a photography station to document changes 
in construct size at the cessation of cultures. With high doses of BMP-2 and bFGF (noted by the presence of 
“h” in the media treatment conditions above), constructs possessed a smooth and regular appearance and were 
larger in size as compared to their low dose counterparts (noted by the presence of “l” in the media treatment 
conditions).  Cultures treated with Complete Culture Medium (CCM) are shown. Interestingly, while treatment 
with CCM resulted in early condensation of cultures (Figure 2.5), long term culture in CCM resulted in 
cultures with substantial fragmentation, surface irregularity, and in contrast to all other treatment conditions, 




At 21 days, constructs treated with CCM, dexamethasone and TGF-3 (DT) and the 
lower doses of BMP-2 and bFGF were consistently smaller in size and irregular in shape 
(Figure 2.6, top row). In contrast, cultures treated with dexamethasone, TGF-3 and 
higher dosing combinations of BMP-2 and bFGF were larger in size and more uniformly 
spherical in size (Figure 2.6, bottom row). These subjective observations indicate that in 
order to produce larger long-term cMSC/collagen gel cultures, TGF-3 and higher doses 
of BMP-2 and bFGF may be required. Quantitative assessment of these cultures at day 3 
and day 21 is provided in Figure 2.7. These results demonstrate the effect of early 
condensation on long-term construct weight for most of the treatment conditions. 
Importantly, cultures treated with DTB(h), DTB(h)F(l) and DTB(h)F(h) maintained 
culture weights across the 21 day time course. In fact, cultures treated with the medium 
DTB(h) were the only treatment condition to result in an increase in construct weight 
over time.  
Visual assessment of viability 
In order to assess cell viability and apoptosis during the initial stages of culture, 
viability was assessed with live/dead staining at day 0 (Figure 2.8) and day 3 (Figure 
2.9). Representative 10X objective overlay images of live and dead fluorescence at day 0 
demonstrated that a majority of the cells stained with calcein (green = calcein positive) 
shortly after collagen gel polymerization. This figure demonstrates that the trypsinization 
and processing methods did not subjectively lead to substantial cell stress or apoptosis at 








Figure 2.7: cMSC/collagen type I culture weight at day 3 and day 21. Constructs from Phase 1 experiments 
(n=3 constructs/treatment condition) were removed from media at day 3 or day 21. Residual moisture from 
media was removed from the surface of constructs using filter paper. Construct weight was next determined.  
Data were reported as mean +/- S.D. for day 3 (black bars) or day 21 (gray bars) for each treatment condition. 
Note that day 21 weights of DTB(h), DTB(h)F(l) and DTB(h)F(h) were similar or higher compared to day 3 









Figure 2.8: Subjective cytotoxicity assessment of cMSC/collagen type I constructs via live/dead staining at day 
0. P2 cMSCs (approximately 70-80% confluence) were washed twice with PBS, trypsinized, lifted, and 
centrifuged at 500xG for 5 minutes. A second wash using medium without serum was performed to remove 
residual serum. Cells were counted and suspended in a 5 mg/ml collagen type I gel at 10 x 106 cells/mL in 100 
µL volumes. Cultures were incubated at 37°C and 5% CO2 for 30 minutes to induce collagen gel 
polymerization. Upon polymerization, two PBS washes were performed and cultures were incubated at 37°C 
for 30 minutes in 500 µL of PBS containing 0.2 µM calcein (Sigma) and 100 µg/mL propidium iodide 
(Botinium, Hawyard, CA). Constructs were subjectively evaluated for live/dead staining using an Olympus 
microscope and fluorescent microscopy. Individual images of live or dead staining were obtained and 
representative images of day 0 constructs are provided above (left panels). Images were merged and an overlay 
produced for each construct using SPOT software (version 5.1; Sterling Heights MI). At completion of cell 
processing and collagen gel polymerization (day 0), constructs contained a large proportion of live (green= 
calcein positive) cells, with a relatively low number of dead cells (red = propidium iodide positive) (Bar = 100 
µm, Obj. = 10X). Note the relatively round or spherical appearance of cells at the time of gel polymerization. 
These images demonstrate the cell processing and construct fabrication did not lead to acute necrosis of 







Figure 2.9: Subjective cytotoxicity assessment of cMSC/collagen type I constructs via live/dead staining at day 3. 
cMSC cultures were incubated for 3 days at 37°C and 5% CO2. Cultures were washed with PBS twice and were 
incubated at 37°C for 30 minutes in 500 µL of PBS containing 0.2 µM calcein (Sigma) and 100 µg/mL 
propidium iodide (Botinium, Hawyard, CA). Constructs were subjectively evaluated for live/dead staining using 
an Olympus microscope and fluorescent microscopy. Individual images of live or dead staining were obtained. 
Live and dead images of each construct were merged and an overlay produced using SPOT software (version 5.1; 
Sterling Heights MI). Representative examples of Phase 1 treatment group overlay images are shown above. At 
day 3, constructs contained a large proportion of live (green= calcein positive) cells, with a relatively low number 
of dead cells (red = propidium iodide positive) (Bar = 100µm, Obj. = 10X) with transition of the most superficial 
cells to a spindle or mesenchymal phenotype. There is some propidium iodide uptake near the center of the 
pellets (top of each image) which indicates some degree of apoptosis within the deeper region of the cultures. 




live/dead staining for five of the growth factor combinations evaluated in Phase 1 are 
shown in Figure 2.9. Three days after initiation of culture, there was a predominant 
staining with calcein (green).  In contrast, cells staining with propidium iodide (red) 
were only occasionally noted. While the results presented in Figures 2.5-2.7 demonstrate 
the effect of growth factor combination and dose on initial condensation and long term 
construct shape and size, using live/dead staining there was subjectively no detectible 
difference in viability of the cells at day 3 of culture in response to the growth factor 
combinations described in Figure 2.9. These results indicate that at the initiation of 
cultures (day 3), growth factor treatment group does not appear to have a major effect on 
the proportion of live or dead cells for cells located within the periphery of our cultures. 
Histopathology 
Representative histopathology of select growth factor combination is shown in 
Figure 2.10. Due to the size of the evaluated constructs, the histological appearance of 
the 21 day cultures was quite diverse and uniform chondrogenic differentiation was not 
noted throughout any of the evaluated constructs. In a number of conditions, groups of 
primitive mesenchymal cells were organizing as though they were differentiating down a 
chondrocyte lineage.  In these areas, the extracellular matrix (ECM) stained blue to 
purple with Toluidine blue and pink to orange with Safranin O.  These special stains 
suggest that the ECM in these regions contains proteoglycans. These findings are 
particularly clear in Figure 2.10A, DTB at a low dose of BMP-2 (50 ng/mL). Cultures 














Figure 2.10: Histologic assessment of cMSC/collagen type I constructs at 21 days. Phase I cMSC cultures were 
prepared as described and incubated in the described media combinations for 21 days with media exchange twice 
weekly. Cultures were gently washed with PBS and fixed in 10% neutral buffered formalin (NBF). Cultures were 
embedded, processed for histology, and assessed using H&E, Toluidine blue, and Safranin O. A) DTB(l). The 
black arrows highlight the primitive mesenchymal cells moving towards a chondrocyte phenotype with 
supporting positive Toluidine blue and Safranin O stain. (bar=100µm). B) DTB(h). The black arrows highlight 
the primitive mesenchymal cells moving towards a chondrocyte phenotype staining purple with supporting 
positive Toluidine blue and Safranin O stain. The asterisk indicates a loosely interwoven myxomatous 
arrangement of cells that do not stain with Toluidine blue or Safranin O. The white stars denote the appearance of 
a zone of deep necrosis within the construct (bar = 500µm). C) DTB(h)F(l). The black arrows highlight the 
primitive mesenchymal cells moving towards a chondrocyte phenotype with supporting positive Toluidine blue 
and Safranin O stain. The asterisks indicate a loosely interwoven myxomatous arrangement of cells that do not 
stain with Toluidine blue or Safranin O. The white stars denote the appearance of a zone of deep necrosis within 
the construct. Arrowheads denote a fibrous capsule that forms in the presence of bFGF (bar = 400µm). D) 
DTB(h)F(h). The black arrows highlight the primitive mesenchymal cells moving towards a chondrocyte 
phenotype. Asterisks indicate a loosely interwoven myxomatous arrangement of cells that do not stain with 
Toluidine blue or Safranin O. The white stars denote the appearance of a zone of deep necrosis within the 




contained a peripheral rim of poorly organized myxomatous tissue with a distribution of 
mesenchymal cells that did not stain for proteoglycans as evidence in Figure 2.10C 
(asterisks). In contrast to the loosely interwoven myxomatous matrix present in cultures 
containing BMP-2, cultures treated with low and high doses of bFGF demonstrated a 
spindle shaped, organized fibrous peripheral rim of tissue (Figure 2.10C,D, arrowheads).  
Importantly, regardless of the growth factor treatment group, the cells within the center 
of the constructs appeared non-viable, with evidence of either apoptosis or necrosis (loss 
of cell structure, pyknosis). Central regions of presumptively non-viable cells are shown 
in Figure 2.10 (white stars).  
In Phase 1, construct morphometry, live dead staining, and histopathology were 
used to identify potentially promising chondrogenic growth factor conditions for cMSCs 
cultured in a 3D collagen type I scaffold and treated with ten various combinations of 
growth factors. Based on the results of Phase 1 experiments, we selected the following 
conditions for additional quantitative evaluation in Phase 2 experiments: dexamethasone, 
TGF-3 (DT), dexamethasone, TGF-3, BMP-2 (500 ng/mL) (DTB), dexamethasone, 
TGF-3 , bFGF (100 ng/mL) (DTF) and dexamethasone, TGF-3 , BMP-2 (500 ng/mL) 
and bFGF (100 ng/mL) (DTBF). 
Phase 2 
Quantitative assessment of cytotoxicity/apoptosis with the Lactate Dehydrogenase 
(LDH) assay 
Cytotoxicity of the cMSC/collagen gel constructs was quantitatively assessed by 
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assaying LDH levels in conditioned media at day 1 and day 3 (Figure 2.11). There was a 
significant increase in overall LDH levels at day 3 as compared to day 1 (p<0.0001). 
When comparing growth factor combinations within each day, there were no detectible 
differences in growth factor combinations at day 1. In contrast, there was a significant 
decrease in LDH levels in cultures treated with the combination of DTBF as compared 
to DTF (p=0.0024), DTB (p=0.0067) and DT (p=0.0024). While one interpretation of 
these data is that cell stress and apoptosis increases at day 3 as compared to day 1. It is 
important to remember that at day 1, media were conditioned for 24 hours. For day 3 
samples, media were conditioned for 48 hours.  As such, the amount of time in which 
LDH was allowed to accumulate was longer for the day 3 time point.  This confounding 
variable makes it difficult to definitively state that day 3 cultures were experiencing 
more stress/apoptosis than day 1 cultures. Regardless, results of this experiment suggest 
that the growth factor combination DTBF leads to reduced cell stress during early stages 
of culture when assessed using the LDH assay. 
Quantitative assessment of total glycosaminoglycan (GAG) content 
Due to the fact that cartilage is a GAG and proteoglycan rich tissue, we 
proceeded to evaluated total GAG content using a colorimetric, 1,9-dimethyl-methylene 
blue (DMMB) based assay at day 3, 10 and 21 (Figure 2.12). There was a significant 
difference in total GAG content when evaluated over time (days in culture) (p=0.0096). 
At day 3, GAG levels were significantly higher in DTBF constructs than DT (p=0.0083), 













Figure 2.11:  Quantitative assessment of cMSC cytotoxicity in early cMSC/collagen type I cultures using a 
Lactate Dehydrogenase (LDH) assay. Based on the results of phase 1 studies, four media treatment conditions 
were selected for quantitative analysis. Cultures were established as described and were incubated for 1 or 3 
days. At each time point, conditioned media were collected for evaluation (n=3 wells/treatment group) and 
stored at -20°C. At completion of the experiment, media were thawed and LDH quantified using a colorimetric 
LDH assay.  LDH levels (ng/mL) were determined by plotting absorbance against an LDH standard curve. 
Data are reported as mean ± S.D. LDH levels for each treatment condition at day 1 or day 3 are reported. 
Letters denote significant differences between growth factor combinations (p<0.05). Additionally, there was a 



















Figure 2.12: Quantitative assessment of glycosaminoglycan (GAG) in cMSC cultures. Based on the results of 
phase 1 studies, four media treatment conditions were selected for quantitative analysis. Cultures were established 
as described and were incubated for 3, 10, or 21 days. At each time point, constructs were removed from media, 
and digested in 500 µL of papain digestion buffer (n=3 constructs/condition) for 3 hours with gentle mechanical 
agitation. Eppendorf tubes containing digested constructs were centrifuged and the supernatant was transferred to 
new tubes and stored at -20°C.  Upon completion of the experiment, samples were thawed at room temperature and 
total GAG was determined using a colorimetric GAG assay. To determine the basal GAG levels in our collagen 
type I, equal volumes of blank collagen type I gel (5 mg/mL) were assayed in the absence of cMSCs (far left). 
Absorbance values were determined and total GAG content (µg/mL) was determined using a known GAG standard 
curve. GAG levels were reported as mean ± S.D. for each media condition and time point. Letters denote 
significant differences between growth factor combinations (p<0.05) within each time point. There was a 




in DTB constructs than DT (p<0.0001), DTF (p<0.0001) and DTBF (p=0.0001). 
Interestingly, in the absence of BMP-2 or bFGF, cultures (DT) had lower GAG 
content as compared to DTB (p<0.0001), DTF (p=0.0206) and DTBF (p=0.0012). At 
day 21, there was a significant increase in GAG content in both DTB and DTBF groups 
as compared to DT (p<0.0001) and DTF (p<0.0001). As was the case at day 10, there 
was a significant decrease in GAG content in cultures treated with DT as compared to 
DTB (p<0.0001), DTF (p<0.0001), and DTBF (p<0.0001). These results suggest that 
GAG content increased over time in the cMSC/collagen gel constructs, and that the 
growth factor combinations DTB and DTBF produced the highest total GAG levels over 
time. To our knowledge this is the first instance in which GAG levels have been 
quantitatively assessed in chondrogenic differentiation of cMSCs.  
Quantitative assessment of gene expression during chondrogenesis of cMSCs using 
qPCR 
Finally, real-time (q)PCR was used to assess transcriptional changes of cMSC 
cultures using a panel of six genes of interest (Figure 2.13). cMSC/collagen gel 
constructs were evaluated at day 3, day 10, and day 21 for transcriptional changes of the 
chondrogenic genes collagen type II, alpha chain (COL2A), aggrecan and the 
chondrogenic transcription factor SOX9.  Constructs were assessed for transcriptional 
















Figure 2.13: Quantitative assessment of gene transcription in cMSC/collagen type I cultures. Based on the results 
of phase 1 studies, four media treatment conditions were selected for quantitative analysis. Cultures were 
established as described and were incubated for 3, 10, or 21 days. At each time point, constructs (n=6 
constructs/condition) were digested in a 2.5 mg/mL bacterial collagenase solution for up to 3 hours in 1.7 mL 
Eppendorf tubes with gentle manual agitation. Upon successful digestion, tubes were centrifuged at 1,000xG for 
10 minutes.  Supernatant was removed and the pelleted cells were lysed using 660 µL of cell lysis buffer followed 
by mRNA isolation according to manufacturer instructions (Dynabeads mRNA Direct purification kit, Thermo-
Fisher Sci., Rockford, IL). mRNA were quantified and 30 ng of mRNA from each sample were used to generate 
cDNA. Real-time PCR (qPCR) was performed for 6 canine genes of interest. All genes were normalized to two 
housekeeping genes (RPL32 and RPL13A) and expression was reported as mean +/- S.D. relative to mRNA 
isolated from cMSCs at day 0. Representative gene expression for: A) Collagen Type I, B) Collagen Type II, C) 
Sox 9, D) Aggrecan, E) Osteocalcin, and F) Osterix. Letters denote significant differences between growth factor 
combinations (p<0.05). There were significant differences in gene expression at day 3, day 10 and day 21 within 
the growth factors. P Values: Collagen Type I (p=0.0001), Collagen Type II (p<0.0001), Aggrecan (p=0.0001), 
Osteocalcin (p=0.0004) and Osterix (p=0.0014). We were unable to detect a significant difference between gene 




transcription factor osterix as previously described (Neupane et al., 2008). Collagen type 
I gene expression was also assessed, alpha chain (COL1A1).  
There was a modest yet significant increase in the relative expression of collagen 
type I over time, regardless of the growth factor treatment condition (p=0.0001) (Figure 
2.13A). There was no detectible effect of the treatment groups on expression of this gene 
(p=0.2559). This finding suggests that while collagen type I was used to create 3D 
constructs with cMSCs, suspension in collagen type I did not result in substantial 
increases in the expression of collagen type I as assessed by qPCR.  
In contrast, there was a dramatic increase in collagen type II gene expression 
over time, with collagen type II expression increasing approximately 50,000 – 100,000 
fold by 21 days of culture (p<0.0001) (Figure 2.13B). Although we did not detect 
significant differences in growth factor combinations at day 3 and 10, at day 21 there 
was a significant decrease in collagen type II expression in DT when compared to DTB 
(p<0.0001) and DTBF (p=0.0036). There was a significant increase in collagen type II 
expression in cultures treated with DTB as compared to DTF (p<0.0001), DTBF 
(p<0.0001) and DT (p<0.0001). These results demonstrate that our chondrogenic 
treatment conditions induced collagen type II expression over time, DTB resulted in the 
greatest increase in collagen type II expression, whereas, the absence of BMP-2 or bFGF 
resulted in the lowest expression of collagen type II over time. 
There was no detectible difference in the relative expression of SOX9 gene 
expression over time (p=0.0644) (Figure 2.13C). However, at day 21, SOX9 expression 
was significantly increased in cultures treated with DT as compared to DTB (p=0.0053), 
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DTF (p=0.0195) and DTBF (p =0.0036). These results were surprising in the context of 
our collagen type II and aggrecan findings (see below).  These results suggest that while 
BMP-2 and bFGF are important in up-regulation of the chondrogenic genes, collagen 
type II and aggrecan, they may also induce osteogenic as well as chondrogenic events 
(see osteogenic gene results below). 
There was a significant increase in the relative expression of the proteoglycan 
aggrecan over time (p=0.0001) (Figure 2.13D). While we were unable to detect 
differences in relative expression of aggrecan at day 3, at day 10 there was a significant 
increase in aggrecan expression in response to DTB as compared to DT (p<0.0001), 
DTF (p<0.0001) and DTBF (p<0.0001). At day 21, there was a significant increase in 
the relative expression of aggrecan in culture treated with DTB as compared to DT 
(p<0.0001), DTF (p<0.0001) and DTBF (p= 0.0003). Moreover, cultures treated with the 
growth factor combination DTBF had statistically higher aggrecan expression as 
compared to DTF (p=0.0004) and DT (p=0.0002). These results closely followed the 
collagen type II expression profile presented in Figure 2.13B and suggest that the growth 
factor combinations DTB and DTBF may be superior canine chondrogenic media 
conditions when assessed by qPCR. 
When assessing the osteogenic associated genes osteocalcin and osterix, there 
was a significant increase in the expression of osteocalcin over time (p=0.0004) (Figure 
2.13E). While we were unable to detect differences in expression of osteocalcin at day 3, 
there was a significant increase in osteocalcin expression at day 10 in cultures treated 
with DTBF as compared to DT (p= 0.0007) and DTB (p= 0.0007). Cultures treated with 
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DTF had significantly higher osteocalcin expression as compared to DT (p=0.0013) and 
DTB (p=0.0013). At day 21, there was a significant increase in osteocalcin expression in 
cultures treated with DTF as compared to DT (p<0.0001), DTB (p<0.0001) and DTBF 
(p=0.0003).  
Lastly, there was a significant increase in osterix expression over time 
(p=0.0014) (Figure 2.13F). Although we were unable to detect differences in the relative 
expression of osterix at day 3, at day 10, cultures treated with DT had a significantly 
lower osterix expression as compared to DTB (p=0.0280), DTF (p=0.0049) and DTBF 
(p=0.0041). At day 21, cultures treated with DT had a significantly lower osterix gene 
expression as compared to DTB (p=0.0265) and DTF (p=0.0218). Although visually 
there was greater osterix expression in cultures treated with DTBF as compared to DT, 
these differences were not significantly different (p=0.1838). These results suggest that 
the presence of the growth factors BMP-2 and bFGF, while increasing expression of the 
chondrogenic genes, collagen type II and aggrecan, may also activate the osteogenic 
pathway (as assessed by osteocalcin and osterix qPCR). 
 
DISCUSSION 
The objective of this study was twofold: first, to develop an improved assay 
system to perform subjective and quantitative analysis of canine chondrogenesis and 
second, to identify the effect of dose and combination of three chondrogenic growth 
factors known to induce chondrogenesis of human MSCs. We selected collagen type I as 
our 3D scaffold due to its wide availability, biocompatibility, spontaneous self-assembly 
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(Glowacki and Mizuno, 2008), and the fact that collagen type I has been successfully 
used in human and ovine chondrogenic studies (Yokoyama et al., 2005; Zscharnack et 
al., 2010). It is well known that growth factors often induce dramatically different 
cellular responses depending on the dose or available concentration of the growth factor. 
In Phase I studies, we successfully developed a system to place high-density cMSC 
cultures in relatively large 3D collagen type I cultures (Figure 2.3). We next used this 
system to subjectively screen the growth factors TGF-3, BMP-2, and bFGF at multiple 
concentrations or doses. Based on our results of phase 1, cultures treated with higher 
doses of bFGF and BMP-2 produced larger and consistently shaped constructs as 
compared to their lower dose counterparts. Long-term morphometry and photography 
suggested that the combinations DT, DTF (100 ng/mL), DTB (500 ng/mL) and DTBF 
(BMP-2 at 500 ng/mL and bFGF at 100 ng/mL) warranted further quantitative 
assessment.  In phase 2 studies, we demonstrated that in the early phases of culture, the 
medium DTBF reduced cytotoxicity of cultures.  Interestingly, the media conditions 
DTB and DTBF produced the highest glycosaminoglycan levels over a 21 day time 
course. With regards to gene expression, evidence of both chondrogenic and osteogenic 
activity was present in cultures containing BMP-2 and bFGF (DTB, DTF, and DTBF). 
These findings are supported by the diverse histologic appearances of our constructs, 
which contained regions of presumptive chondrogenic differentiation as well as 
transitional type cells that may represent the initiation of the endochondral ossification 
pathway.   
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In summary, this project has demonstrated the effectiveness of the system in 
performing subjective and quantitative assessment of canine chondrogenesis. Moreover, 
using a variety of subjective and quantitative assessment tools, the media conditions 
DTB and DTBF appear to be the most promising for future canine bone marrow-derived 
MSC chondrogenic studies.  At the time of this writing, it is unable to be determined if 
DTB or DTBF is a superior chondrogenic culture medium.  
Previous studies have demonstrated the difficulty in inducing repeatable 
chondrogenic differentiation using cMSCs and the traditional micromass culture method 
(Kisiel et al., 2012). Furthermore, our lab has demonstrated the difficulty working with 
the micromass system using cMSCs as the constructs fragment easily and are smaller 
than 1 mm in size making the future option of clinical translation difficult. In other in 
vitro model systems, bFGF was required for cMSC invasion and survival (WB et al., 
2017). In human chondrocyte studies, bFGF was noted to enhance proliferation and 
delay the loss of chondrogenic potential.  
Due to the biphasic effect of growth factors, both a low and high concentration of 
bFGF and BMP-2 were evaluated in combination with traditional concentrations of 
dexamethasone and TGF-3. This effect of growth factor dose was noted when 
evaluating the size and shape of chondrogenic constructs (Figure 2.6).  Media containing 
the higher concentrations of growth factors [DTB(h), DTF(h), DTB(h)F(h)] produced 
constructs with consistent shape and regular margins compared to those with low 
concentrations and the control medium. At day 3, all constructs with TGF-3 underwent 
condensation. This is similar to that seen in vivo as TGF-s have been implicated in the 
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modulation of N-cadherin expression levels (Tuli et al., 2003). These modulations likely 
control condensation–like cell-cell and cell-matrix interactions which then lead to 
chondrogenic differentiation (Chimal-Monroy and Díaz de León, 1999; Tuli et al., 
2003).  
Lastly, assessment of construct weight over time suggested that high doses of 
BMP-2 or bFGF were required to maintain or increase culture weight over the 21 day 
time course (Figure 2.7).  
When quantitatively assessed, there was a statistically significant difference in 
cytotoxicity between day 1 and day 3 for all four growth factor combinations in phase 2. 
This suggests that the cells were undergoing more stress at day 3 when compared to day 
1. However, it is important to note that at day 1, the cells were provided with 750 uL of 
medium. This medium was then removed after 24 hours for day 1 analysis and the 
constructs were provided with fresh media. After 48 hours (day 3), the medium was 
removed for day 3 analysis. Thus, the statistically significant increase between days 
could be accounted for by the extra 24 hours the media had in contact with the 
constructs. When evaluating the difference between growth factors at a fixed time point, 
at day 3, cultures treated with DTBF produced significantly lower LDH levels when 
compared to the other three growth factor treatments. This suggested that in early 
culture, the addition of bFGF may be somewhat protective.  Admittedly, LDH levels 
were not continuously assessed over time and as such, the long-term effects of bFGF in 
cultures is still unknown. The timing of the delivery of bFGF is certainly worthy of 
additional investigation and will be the focus of future studies. 
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One component of articular cartilage which allows resilience is 
glycosaminoglycan (GAG) content. When evaluating the GAG content of the cMSC 
cultures at day 3, DTBF produced higher GAG levels as compared to the other three 
growth factor combinations. At day 10 DTB surpassed DTBF and DTF and finally by 
day 21 both DTB and DTBF produced the highest GAG levels.  These results 
demonstrate that DTB and DTBF result in the greatest GAG accumulation over time.  
However, it is important to note that this assay measures total GAG content. Thus, the 
large increase in glycosaminoglycan content at day 3 for each growth factor combination 
compared to that of collagen type I should be interpreted with caution. GAGs are present 
within cells, on the cell surface and in the cell-produced ECM. Thus, this assay measures 
all three cell and matrix spaces and we are not able to distinguish between those 
deposited in the ECM against those produced in the cell and on the cell surface.   
Nevertheless, while ECM staining was not uniformly robust, our histology results 
suggest GAG accumulation within the ECM in various portions of the constructs (Figure 
2.10). 
One challenge of working with the canine species as a model system is the 
relative paucity of known working primer sets for genes of interest. A small number of 
osteogenic and chondrogenic genes of interest have been previously described by 
Neupane et al and others (Neupane et al., 2008; Nicholson et al., 2007; Peters et al., 
2007). Using these sequences, qPCR was performed at early, middle, and late time 
points using a panel of six genes of interest. All gene expression was normalized to two 
housekeeping genes (RPL13A and RPL32), based on the stability of these genes in a 
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majority of tissues in a thorough paper evaluating housekeeping genes in various dog 
tissues (Peters et al., 2007). Expression was reported relative to the number of copies 
present within cells at the initiation of each experiment.  
The presence of BMP-2 and bFGF in various combinations resulted in increased 
expression of collagen type II and aggrecan when compared to cultures treated with 
media containing dexamethasone and TGF-3. Interestingly, the greatest increase in the 
expression of SOX9, a master transcription factor for chondrogenesis, occurred in 
cultures treated with medium containing dexamethasone and TGF-3. The presence of 
BMP-2 or bFGF resulted in a dampening of SOX9 expression. These results suggest that 
while BMP-2 and bFGF certainly led to regional chondrogenesis as assessed by 
histology and supported by qPCR and GAG data, the presence of these growth factors 
may also dually activate osteogenic differentiation pathways. In support of this concept 
of dual differentiation, the presence of bFGF led to significant increases in osteocalcin 
expression and the presence of BMP-2 and/or bFGF led to significant increases in 
osterix gene expression. These results suggest that while chondrogenic activity is 
occurring, the addition of the growth factors BMP-2 and bFGF led to some degree of 
osteogenic activity. These results may account for some of the changes seen 
histopathologically and may indicate the possibility of endochondral ossification.  
Additional studies are warranted to evaluated this important finding. 
While the histologic findings of focal/regional chondrogenic activity initially 
appear discouraging, to the author’s knowledge, the methods described in this thesis are 
the first to successfully allow consistent assays of chondrogenesis with canine bone 
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marrow-derived MSCs. As such, this work represents a significant advance in the field 
of cMSC chondrogenesis. The finding of regional chondrogenesis may be due to the 
large increase in construct size when compared to the traditional micromass culture 
system initially described by Sekiya et al (Sekiya et al., 2002). Our initial studies 
concluded at 21 days. As such, it is possible that cultures may continue to undergo 
differentiation over time. Additional experiments would be necessary to evaluate this 
possibility.  
Within the most promising areas of differentiation, primitive mesenchymal cells 
that morphologically adopted a cartilage phenotype produced ECM that stained positive 
with both Toluidine blue and Safranin O. Despite these findings, it is difficult to 
determine whether these areas are indicative of primitive chondrogenesis or other 
differentiation processes such as endochondral ossification where a cartilage 
intermediary is transformed into bone. With endochondral ossification, chondrocytes 
become terminally differentiated to a hypertrophic phenotype increasing their cellular 
fluid volume by almost 20 times (Goldring and Tsuchimochi, 2006). Morphologic 
evidence of chondrocyte hypertrophy in the histologic sections evaluated in this study 
were not noted. Once these chondrocytes undergo hypertrophy, they begin to express 
collagen type X and alkaline phosphatase (Goldring and Tsuchimochi, 2006). To further 
evaluate the possibility that our cultures contain early endochondral ossification, 
collagen type X gene expression or immunohistochemistry could be evaluated using 
qPCR. Although the canine genome is sequenced, functional primer sets for collagen 
type X are undescribed and would need to be validated prior to use in our system.  
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Lastly, treatment of our 3D cultures with each of the growth factor combinations 
resulted in the presence of a zone of necrosis in the central aspect of cultures. TUNEL 
staining or active caspase immunohistochemistry would be necessary to confirm this 
appearance. A reason for the central zone of necrosis may include a larger diffusion 
distance for nutrient and waste exchange. Zones of necrosis within the central area of 
chondrogenic cultures have been previously reported (Kisiel et al., 2012; Liangming 
Zhang et al., 2010) in both human and canine MSC studies. Zhang et al., hypothesized 
that these changes may be explained by the difference in oxygen tension in the 
environment with extremely high cell density resulting in poor nutrient diffusion 
(Liangming Zhang et al., 2010). As the optimum oxygen tension and cell density 
combination has yet to be determined for canine chondrogenesis, additional studies are 
likely warranted to test this hypothesis. Interestingly, pilot experiments were performed 
in which cMSCs were expanded under hypoxia and transitioned to normoxia during 
chondrogenesis while also performing the reverse treatment conditions (normoxia to 
hypoxia). These treatments did not dramatically alter the chondrogenic process when 
assessed histologically (unpublished observations).  
Limitations of the work described in this thesis include the use of only one 
preparation of canine MSCs which were isolated from the bone marrow of a healthy 
intact Walker Hound.  As such, the effect of donor age, sex, health, and tissue source of 
MSCs on canine chondrogenesis in this model system remain unknown. As noted above, 
the qPCR panel was somewhat limited as compared to other model systems. Admittedly, 
the ability to quantitatively assess early live and dead cells was prevented by the large 
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3D nature of the constructs and the inability to use fluorescence to image through these 
constructs without mechanically sectioning through the gels. Furthermore, the methods 
and growth factor combinations described in this study did not result in widespread 
chondrogenesis when the pellets were evaluated via histopathology, despite the fact that 
GAG content and qPCR results provided evidence for chondrogenic differentiation. 
While there are potentially an unlimited number of growth factors and growth factor 
combinations worthy of evaluation, we only focused on a select number of growth 
factors. Lastly, this system relies on collagen type I as opposed to the collagen type II 
found in articular cartilage.   
Despite these limitations, the system defined in this report allows assessment of 
cMSC differentiation events using a variety of both subjective and quantitative 
assessment tools. This system is suggested by the authors to prove useful for additional 
mechanistic studies aimed at defining canine chondrogenesis. It may also prove useful as 
a foundation for translational work in which cMSCs are induced toward chondrogenesis 
in a collagen scaffold and utilized to treat focal cartilage defects in canine experimental 





CONCLUSIONS AND FUTURE DIRECTIONS 
 
This thesis outlines the importance of addressing the clinical and economic 
burden accompanying focal articular cartilage defects, such as those caused by the 
developmental orthopedic disease, osteochondrosis, as well as by localized joint trauma.  
The purpose of the work presented within this thesis was to develop an in vitro serum-
free collagen type I system to evaluate cMSC chondrogenesis using a number of 
subjective and quantitative assessment tools. Once established, the effect of the growth 
factors TGF-3, BMP-2, and bFGF on cMSC chondrogenesis were determined. This 
work serves as a significant advance in canine chondrogenesis and may serve as a 
launching point for future translational studies in vivo.  
In Chapter II, specific combinations of TGF-3, BMP-2 and bFGF were 
combined with cMSCs and a collagen type I scaffold for evaluation of chondrogenic 
differentiation in two sets of experiments: Phase 1 (a screening experiment) and phase 2 
(a quantitative assessment of cytotoxicity and chondrogenesis). Results of phase 1 
demonstrated that chondrogenic media containing the higher dosages of BMP-2 and 
bFGF produced larger, heavier and consistently shaped constructs, which may prove to 
be more amenable to translation to the clinical setting. Importantly, cell handling and 
construct fabrication did not affect cMSC health at day 0 as assessed visually using 
live/dead staining. Subjectively, there was no difference in live/dead staining results 
across any of the growth factor combinations at day 3. Furthermore, histologic 
assessment revealed focal regions of mesenchymal cells organizing in a chondrogenic 
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phenotype, particularly in cultures treated with dexamethasone, TGF-3, BMP-2 (DTB) 
and dexamethasone, TGF-3, BMP-2, and bFGF (DTBF).  In phase 2, cytotoxicity was 
evaluated during early stages of cultures and total GAG content was determined at 3, 10, 
and 21 days. Treatment of cMSC constructs with medium containing DTBF reduced cell 
stress and apoptosis early in culture when compared to the other growth factor 
combinations. These results suggest that the incorporation of bFGF may be 
advantageous during initiation of cMSC chondrogenic cultures. Moreover, constructs 
treated with media containing DTB and DTBF had significant increases in total GAG 
content at day 21, suggesting that, in this in vitro canine system, these growth factor 
combinations are capable of producing constructs that accumulate GAG over time. 
Finally, assessment of gene expression using qPCR demonstrated an up-
regulation of both osteogenic and chondrogenic genes during the course of our 
chondrogenic cultures. These results suggest that that multiple differentiation processes 
may be occurring within different regions of the constructs. These findings were 
supported by histopathology as small distinct regions were seen to undergo 
chondrogenic differentiation and stain with Toluidine blue and Safranin O. There were 
no areas indicative of hypertrophic chondrocytes and thus, endochondral ossification, 
given the osteogenic and chondrogenic gene expression on qPCR, was less likely. 
Additional assessment of histological sections using TUNEL staining and 
immunohistochemistry for collagens type II and X are currently under consideration.  
Collectively, the results presented in Chapter II demonstrate that the 3D serum-free 
collagen type I system is useful for cMSC differentiation assays. Both subjective and 
 
 71 
quantitative assessment measures were developed to assess chondrogenesis representing 
an advance for the field of canine chondrogenesis.  
Future studies however, are necessary to further elucidate the molecular 
mechanisms of canine chondrogenesis. From a clinical perspective, additional work is 
necessary to determine if tissue type or donor variability will impact chondrogenesis 
using this system.  Additionally, in order to fabricate larger constructs for implantation 
in larger animals or human beings, future studies may be necessary to fuse early 
chondrogenic cultures as was recently demonstrated with hMSCs (Bhumiratana et al., 
2014). The results of these future experiments may lead to novel regenerative medicine 
and tissue engineering treatments, which will ultimately address many of the 
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